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Abstract 
Ketrija Touw 
 
DIFFERENTIATION AND CONTRACTILITY OF COLON SMOOTH MUSCLE 
UNDER NORMAL AND DIABETIC CONDITIONS 
 
Intestinal smooth muscle development involves complex transcriptional 
regulation leading to cell differentiation of the circular, longitudinal and muscularis 
mucosae layers. Differentiated intestinal smooth muscle cells express high levels 
of smooth muscle-specific contractile and regulatory proteins, including telokin. 
Telokin is regulatory protein that is highly expressed in visceral smooth muscle. 
Analysis of cis-elements required for transcriptional regulation of the telokin 
promoter by using hypoxanthine-guanine phosphoribosyltransferase (Hprt)-
targeted reporter transgenes revealed that a 10 base pair large CC(AT)6GG cis-
element, called CArG box is required for promoter activity in all tissues. We also 
determined that an additional 100 base pair region is necessary for transgene 
activity in intestinal smooth muscle cells. To examine how transcriptional 
regulation of intestinal smooth muscle may be altered under pathological 
conditions we examined the effects of diabetes on colonic smooth muscle. 
Approximately 76% of diabetic patients develop gastrointestinal (GI) symptoms 
such as constipation due to intestinal dysmotility. Mice were treated with low-
dose streptozotocin to induce a type 1 diabetes-like hyperglycemia. CT scans 
revealed decreased overall GI tract motility after 7 weeks of hyperglycemia. 
Acute (1 week) and chronic (7 weeks) diabetic mice also had decreased 
potassium chloride (KCl)-induced colon smooth muscle contractility. We 
hypothesized that decreased smooth muscle contractility at least in part, was due 
to alteration of contractile protein gene expression. However, diabetic mice 
showed no changes in mRNA or protein levels of smooth muscle contractile 
proteins. We determined that the decreased colonic contractility was associated 
with an attenuated intracellular calcium increase, as measured by ratio-metric 
vii 
imaging of Fura-2 fluorescence in isolated colonic smooth muscle strips. This 
attenuated calcium increase resulted in decreased myosin light chain 
phosphorylation, thus explaining the decreased contractility of the colon. Chronic 
diabetes was also associated with increased basal calcium levels. Western 
blotting and quantitative real time polymerase chain reaction (qRT-PCR) analysis 
revealed significant changes in calcium handling proteins in chronic diabetes that 
were not seen in the acute state. These changes most likely reflect 
compensatory mechanisms activated by the initial impaired calcium response. 
Overall my results suggest that type 1 diabetes in mice leads to decreased colon 
motility in part due to altered calcium handling without altering contractile protein 
expression. 
 
B. Paul Herring Ph.D., Chair 
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CHAPTER I 
 
INTRODUCTION 
 
Structure and functions of the colon 
  
Digestive tract involved in food movement consists of the mouth, pharynx, 
esophagus, stomach, small and large intestine. The colon is a part of the large 
intestine and contains three smooth muscle layers – longitudinal, circular, and 
muscularis mucosae (Figure 1). The longitudinal and circular smooth muscle 
layers together are called the muscularis externa or muscularis propria and are 
responsible for the majority of motility in the colon. The muscularis mucosae is 
located at the border between the mucosal and submucosal layers, and 
promotes movement of the epithelial mucosa. The main functions of the external 
muscle layers are mixing, storage and propulsion of the colon contents. Mixing of 
the chyme within the colon occurs through segmenting contractions of the 
circular smooth muscle layer that promotes fluid and electrolyte absorption. The 
colon also serves as a reservoir of the chyme during water absorption process 
and until defecation of the residual material. Mass peristaltic contractions of 
colonic smooth muscle play an important role in propelling the colonic contents to 
the rectum for excretion. Functionally the colon is subdivided into proximal and 
distal regions. Mixing, storage and removal of water and electrolytes from the 
chyme occurs mainly in the proximal part of the colon. The distal part of the colon 
serves as a main storage reservoir and conduit for feces. 
 
The main function of the smooth muscle is to provide the contractile activity for 
the colonʼs mixing and propulsive movements. To achieve this contractile activity 
the smooth muscle expresses a unique repertoire of contractile and regulatory 
proteins. Understanding how expression of these proteins is regulated under 
physiological and pathological conditions is important for developing appropriate 
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therapies for diseases that affect the contractility of the intestine. The smooth 
muscle contractile regulatory protein telokin is known to be highly expressed 
specifically in visceral smooth muscle tissues and represents a useful target for 
determining regulatory mechanisms that control expression of smooth muscle-
specific genes in normal physiological and disease states. Thus, in my thesis 
research I analyzed telokin transcriptional regulation during development and in 
adulthood and determined if and how this is altered in the diabetic state. Previous 
studies have shown that diabetes in human patients and in different animal 
models leads to colon dysmotility. My research was aimed at determining the 
molecular defects that occur in colon smooth muscle during diabetes and what 
role telokin plays in the development of motility dysfunction associated with the 
disease.     
 
 
Regulation of colonic contractility 
 
Colon smooth muscle contractility is controlled by pacemaker cells within the 
intestinal wall and by the autonomic nervous system (ANS) and enteric nervous 
system (ENS). The ANS consists of sympathetic and parasympathetic nerve 
fibers which can either directly modulate the activity of intestinal smooth muscle 
or can synapse with neurons of the ENS. The ENS is subdivided into two 
interconnected plexuses, the myenteric (Auerbach) plexus located in the 
muscularis externa and the submucosal (Meissner) plexus. The neurons in the 
myenteric plexus primarily regulate contractility of the smooth muscle whereas 
the neurons in the submucosal plexus primarily regulate the activity of the 
mucosal epithelial cells. Interstitial cells of Cajal (ICC) are enteric pacemakers 
that mediate the basic electrical rhythm within the intestine [1]. The slow wave 
depolarization induced by the ICCs are transmitted to and through the intestinal 
smooth muscle cells via GAP junctions. Neurotransmission from nerves to 
smooth muscle can allow these slow waves to reach threshold and fire off action 
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potentials thus opening plasma membrane calcium channels to initiate 
contraction. Alternatively, neurotransmitters can direct pharmacomechanical 
coupling to induce intracellular calcium release via a receptor-inositol 
trisphosphate (IP3) pathway. Vagal parasympathetic nerves from the medulla 
oblongata innervate the upper GI tract down to the proximal part of the colon. 
The parasympathetic nerves from sacral region of the spinal chord innervate the 
distal part of the colon via the pelvic nerves. In general, activation of 
parasympathetic nerves stimulate secretion and promotes motility. Sympathetic 
nerves from the superior mesenteric ganglion (SMG) and inferior mesenteric 
ganglion (IMG) innervate proximal and distal parts of the colon, respectively. 
Sympathetic nerve terminals mainly synapse with the ENS, however some of 
them terminate directly on smooth muscle [2]. Sympathetic nerves usually have 
inhibitory effects on GI smooth muscle motility. 
 
Contraction of GI smooth muscle can be regulated by electromechanical or 
pharmacomechanical coupling. During electromechanical coupling GI smooth 
muscle contraction occurs following voltage dependent activation of L-type 
calcium channels facilitating calcium influx across the plasma membrane [3, 4]. 
In contrast, during pharmacomechanical coupling neurotransmitter or hormone 
binding to specific G-protein coupled receptors, stimulates phospholipase C 
(PLC) activity leading to catalysis of lipid phosphatidylinositol 4,5-bisphosphate 
(PIP2). Catalysis of PIP2 promotes production of two secondary messengers: 
inositol trisphosphate (IP3) and diacylglycerol (DG). IP3 binds to the IP3R on the 
sarcoplasmic reticulum (SR), causing release of calcium into the cytosol.  When 
intracellular calcium rises either as a result of electromechanical or 
pharmacomechanical coupling Ca2+ binds to calmodulin and activates myosin 
light chain kinase (MLCK). MLCK then phosphorylates the light chain of myosin 
stimulating myosinʼs actin-activated ATPase activity and the energy released 
from ATP hydrolysis results in myosin cross-bridge cycling and contraction. 
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When pharmacomechanical coupling occurs, the DG that is produced along with 
IP3 activates PKC, which phosphorylates specific target proteins that can 
modulate contractility. Smooth muscle contractions can also occur in the absence 
of a rise in intracellular calcium through a calcium sensitization mechanism which 
occurs when myosin phosphatase activity is inhibited. For example, activation of 
Ras homolog gene A (RhoA) increases Rho kinase (ROK) activity leading to 
phosphorylation and inactivation of myosin phosphatase (MLCP). Conversely, 
phosphorylation of telokin by PKG plays role in Ca desensitization and smooth 
muscle relaxation. Telokin knock out mice showed increased sensitivity to Ca 
and decreased cyclic guanosine monophosphate (cGMP)-induced relaxation 
[22]. 
 
Intracellular calcium levels in smooth muscle cells are tightly regulated by 
channels and receptors. Smooth muscle stimulation leads to calcium influx into 
cytosol and relaxation causes calcium efflux out of the cell or uptake into SR. As 
mentioned above, voltage gated L-type cannels play the major role in the influx of 
calcium into the cell from the extracellular fluid (Figure 2). Calcium release from 
intracellular stores can be mediated by either the IP3 receptor or the ryanodine 
receptor (RyR). The IP3 receptor (IP3R) is located on the membrane of the SR 
and when stimulated by IP3 triggers calcium release from the SR [4]. RyRʼs are 
stimulated by cytosolic calcium and play role in calcium induced calcium release 
(CIRC) from the SR into the cytosol. Following contraction it is important to 
eliminate calcium from the cytosol in order to facilitate relaxation. 
Sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) is an ATP-dependent 
calcium pump located on the SR that plays a significant role in the reuptake of 
calcium into the SR permitting smooth muscle relaxation. SERCA activity is 
regulated by the protein phospholamban (PLN). When PLN is associated with 
SERCA calcium uptake into the SR is inhibited, while after dissociation from PLN, 
calcium uptake is increased. In cardiac and perhaps also in smooth muscle, 
phosphorylation of PLN relieves its inhibitory activity on SERCA. The plasma 
5 
membrane Ca2+ ATPase (PMCA) is a transporter located in the plasma 
membrane of the smooth muscle that also removes calcium from the cytoplasm 
by pumping it out of the cell. The pump is activated by the hydrolysis of 
adenosine triphosphate (ATP). While it has high affinity for binding calcium, the 
removal of calcium out of the cell by this pump occurs at slow rate. An additional 
mechanism of calcium extrusion is provided by the sodium-calcium exchanger 
(NCX), an antiporter located on the smooth muscle plasma membrane. NCX 
removes calcium from cells in exchange for sodium. In contrast to PMCA the 
Na+/Ca2+ exchanger does not bind very tightly to Ca2+ but it can transport calcium 
out of the cell rapidly. 
 
 
Differentiation and development of the colon smooth muscle  
 
Progenitors of colonic smooth muscle cells differentiate from the mesenchyme 
surrounding the primitive gut epithelial tube. At early stages the primitive gut has 
a tubular form and consists of undifferentiated epithelium surrounded by 
undifferentiated mesenchyme. Smooth muscle development follows a rostro-
caudal progression starting in the esophagus at embryonic day 11 in mice and 
moving forward toward the foregut, midgut and finally the hindgut [5, 6]. The 
smooth muscle precursor cells are called myoblasts and express SM α-actin [5, 
6]. In parallel to villi formation, the first layer of smooth muscle myoblasts 
differentiate and give rise to the inner circular smooth muscle layer. Around 
embryonic day 12 primitive crypts are formed and smooth muscle cells in the 
longitudinal layer differentiate. Coincident with longidudinal smooth muscle 
appearance the third smooth muscle layer muscularis mucosa forms from 
mecenchyme in close proximity to the epithelium. Although the muscularis 
mucosae represents an independent induction of smooth muscle it progresses 
through similar differentiation pattern as circular and longitudinal smooth muscle 
layers. During development, smooth muscle myoblasts rapidly differentiate into 
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smooth muscle myocytes that are immature smooth muscle cells that persist until 
birth [5, 6]. Smooth muscle myocytes, in addition to expressing SM α-actin also 
start to express high levels of SM γ-actin, smooth muscle myosin heavy chain 
(SM-MHC), telokin and calponin from embryonic day 12-13 in mice. However, the 
final differentiation and maturation of myocytes occurs only after birth. 
 
Many signaling pathways are involved in smooth muscle differentiation during 
development of gastrointestinal tract. Hedgehog (Hh) signaling is important for 
radial patterning and mesenchyme differentiation into smooth muscle. Sonic 
hedgehog (Shh), a member of Hh family, has been implicated in the early 
development in the gut and plays role in the crosstalk between endoderm and 
mesoderm. Hh ligand is released by endoderm and induces development of 
smooth muscle [7, 8]. Hh is a radial morphogen and does not promote smooth 
muscle development if mesenchyme is located too close or too far to the source 
of the ligand [7, 8]. It also have been shown that inactivation of Hh signaling 
impairs smooth muscle development [7]. In the developing gut Shh induces 
expression of the Transforming growth factor β (TGFβ) family member Bone 
morphogenetic protein 4 (BMP4) in the mesenchyme which is important factor in 
smooth muscle development [9, 10]. BMP family members are expressed in both 
mesenchyme and epithelial cells. BMP4 has been shown to play role in smooth 
muscle proliferation and differentiation [11]. However, BMP2 rather than BMP4 
enhanced smooth muscle differentiation from embryonic stem cells in an in vitro 
gut differentiation model, as evidenced by enhanced formation of contracting gut-
like structures that expressed SM α-actin [12]. Although Wnt signaling has been 
implicated in the development of epithelial cells, recent studies have also shown 
role of Wnt5a in the differentiation of mesenchyme. Wnt5a knock out mice have 
thinner muscularis propria, improper midgut closure, and a shortened midgut 
[13]. These findings suggest that Wnt signaling plays a role not only in epithelial 
cell proliferation but also mesenchyme proliferation and/or differentiation. 
Fibroblast growth factors (FGF) family members also have been shown to play 
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roles in development of smooth muscle of the colon. For example, FGF-9 has 
been implicated in signaling pathway that controls gut length through proliferation 
and differentiation of fibroblasts [14].  
 
 
Smooth muscle contractile and regulatory proteins 
 
All differentiated smooth muscle is characterized by the presence of unique 
isoforms of contractile proteins that are not expressed in other tissue types. 
Examples of smooth muscle-specific proteins include smooth muscle α and γ -
actin, SM-MHC, caldesmon, SM22α, telokin and calponin. Although all of these 
proteins are expressed in smooth muscle some of them are more abundant in 
visceral smooth muscle while others are more abundant in vascular smooth 
muscle tissue. For example, telokin and SM γ-actin are particularly abundant in 
visceral smooth muscle cells [15-17] while SM22α is highly expressed in vascular 
and visceral smooth muscle in adult animals [18-20]. While the physiological 
functions of myosin and actin are well defined the functions of other smooth 
muscle restricted proteins are less clear. The amino acid sequence of telokin is 
identical to the carboxyl-terminus of the 130kDa “smooth muscle” MLCK and the 
220kDa “non-muscle” form of MLCK (Figure 3). However, telokin does not 
contain the kinase domain of the MLCKs and functions rather to regulate the 
activity of the myosin light chain phosphatase. Telokin has been shown to 
activate myosin light chain phosphatase and to be important for cGMP mediated 
calcium desensitization of phasic smooth muscle tissues [21-25]. Telokin 
knockout mice, generated by deleting an AT-rich region and the CArG box from 
the core of the telokin promoter, exhibit increased myosin phosphatase activity, 
resulting in a leftward shift in the calcium-force relationship in visceral but not 
vascular smooth muscle tissues [22]. The higher level of expression of telokin in 
visceral as compared to vascular and smooth muscle cells can thus account for 
the lower calcium sensitivity of contraction in visceral as compared to vascular 
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tissues [21]. These findings demonstrate that differential expression of telokin in 
distinct smooth muscle tissues plays an important role in regulating the 
physiological properties of the tissue. 
 
SM22α is a smooth muscle-specific protein that binds cytoskeletal actin filaments 
in smooth muscle cells. SM22α knock out mice develop normally and do not 
develop any cardiovascular or visceral organ problems suggesting that it is not 
required for basal homeostatic functions in these tissues [26]. However, when 
SM22α knock out mice were crossed into hypercholesterolemic ApoE-deficient 
mice, mice developed more pronounced atherosclerotic lesions suggesting that 
SM22α plays a role in smooth muscle phenotype regulation during atherogenesis 
[27]. SM22α also have been implicated in calcium-independent vascular smooth 
muscle contractility [28]. Similar to SM22α, calponin has been implicated in the 
regulation of smooth muscle contraction through its interaction with actin and 
inhibition of phosphorylated myosin [29]. Calponin acts as an actin filament-
stabilizing molecule that contributes to physiological thin filament turnover rates 
in different cell types. Another actin-binding protein, caldesmon also binds 
myosin, calmodulin and tropomyosin and plays a significant role in regulating 
contractility by inhibiting the  actomyosin ATPase activity. Caldesmon’s activity 
is regulated by calcium levels and phosphorylation [30]. 
 
 
Transcriptional regulation in smooth muscle 
 
Analysis of the transcriptional regulation of smooth muscle restricted genes such 
as telokin and SM22α has provided important insights into the molecular 
mechanisms that control smooth muscle differentiation. 
 
We have previously shown that telokin mRNA is transcribed from a promoter 
located within an intron that interrupts the exon encoding the calmodulin binding 
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domain of the MLCKs (Figure 3) [16]. Unlike the 130kDa MLCK, which has been 
detected in all adult tissues examined thus far, telokin protein and mRNA 
expression is restricted to adult and embryonic smooth muscle tissues and 
cultured smooth muscle cells [31, 32]. Both, in adult and in embryonic mice, 
telokin is expressed at higher levels in most visceral smooth muscle tissues 
compared to vascular smooth muscle tissues [31]. In situ hybridization analysis 
revealed that telokin expression is first detected in the gut at embryonic day 11.5. 
Expression is then detected in airway and urinary smooth muscle between day 
13.5 and 15.5. Induction of telokin expression during the postnatal differentiation 
of the reproductive tract parallels the induction of other smooth muscle-specific 
proteins. The variable levels of telokin expression, in different vascular smooth 
muscle tissues, likely reflect the diverse origins of smooth muscle cells 
throughout the vasculature. For example, although no telokin could be detected 
in the dorsal aorta of a 14.5 day embryonic mouse, high levels of expression 
could be detected in the umbilical artery [31]. The cis-acting regulatory elements 
necessary to direct this pattern of telokin expression are contained within a 
370bp proximal promoter region, as a reporter gene driven by this fragment was 
also restricted largely to visceral smooth muscle in adult animals in vivo [33].  
 
Analysis of SM22α gene expression reveled that endogenous SM22α is 
expressed in skeletal, smooth and cardiac muscle during embryonic development 
but postnatally becomes restricted to smooth muscle only [34]. SM22α is first 
detected in the primitive heart tube at embryonic day 8, after embryonic day 13.5 
mRNA levels decline in the heart such that no expression can be detected in 
adults. Similarly, transient SM22α expression was also observed in developing 
skeletal muscle between embryonic days 9.5 and 12.5. Postnatally SM22α 
expression is restricted to smooth muscle tissues, although in contrast to the 
endogenous SM22α which is expressed in all smooth muscle tissues, SM22α 
promoter driven transgenes are restricted to vascular smooth muscle tissues [26, 
35, 36]. Several reports have shown that a -441 to +62 SM22α promoter directs 
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reporter gene expression specifically to arterial smooth and not to venous or 
visceral smooth muscle cells in transgenic mice [18-20, 33]. Longer promoter 
fragments exhibited a similar pattern of transgene expression but a BAC clone 
encompassing the entire SM22α gene was found to be expressed in all smooth 
muscle tissues in transgenic mice [18, 19, 36]. These data suggest that 
additional distal regulatory elements are required for SM22α promoter activity in 
veins and visceral tissue.  
 
 
Regulation of smooth muscle-specific genes by serum response factor 
(SRF)  
 
Serum response factor (SRF) is a widely expressed transcription factor that plays 
roles in differentiation of cardiac, skeletal and smooth muscles. SRF regulates 
genes by binding to a 10 bp cis-element, CC(AT)6GG, called the CArG box [37]. 
SRF have been shown to play a role in smooth muscle differentiation and smooth 
muscle-specific gene expression. Mouse knockout studies have shown that SRF 
is important in mesoderm differentiation during mouse embryogenesis [38]. 
Although SRF knock out embryonic stem (ES) cells could form mesoderm in 
vitro, by an unknown mechanism, they were not able to express smooth muscle 
markers [39]. These data suggest that, in addition to regulating mesoderm from 
which most smooth muscle cells are derived, SRF also plays a direct role in 
regulating smooth muscle differentiation. This is supported by studies which 
generated a smooth muscle-specific knockout of SRF in adult tissues [40-42]. 
Knocking out SRF in adult smooth muscle tissues resulted in a dilated GI tract 
with decreased contractility due to attenuated expression of smooth muscle 
contractile proteins and a thinning of the muscularis externa. These defects led to 
severe intestinal obstruction [40, 41]. 
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The promoter regions of most smooth muscle restricted genes contain one or 
more CArG elements that bind (SRF). SM-MHC, α and γ -actin, and calponin 
each have multiple CArG boxes, smoothelin A and SM22α - two CArG boxes and 
telokin only one [18, 32, 43-47]. Combinations of one or two CArG box mutations 
have shown inhibited promoter activity in different smooth muscle subtypes. For 
example, mutations in both CArG elements in the SM22α abolished promoter 
activity in arterial smooth muscle cells [18, 48]. A study using mutation analysis 
of CArG elements within the smooth muscle myosin heavy chain promoter in vivo 
showed that transcriptional regulation of SRF differs among smooth muscle 
subtypes [49]. For example, the CArG box located in the 5ʼ-flanking sequence 
(CArG1) was required for promoter activity in all smooth muscle cells, while the 
CArG box located in the intronic region (CArG2) was important for expression 
more specifically in arteries. Mutation of CArG2 resulted in decreased promoter 
activity in the GI tract, abolished expression in large blood vessels, trachea and 
bronchi while showing weak expression in small vessels and was not affected in 
bladder. Our in vitro studies have also shown that the CArG element within the 
telokin promoter is necessary for telokin expression in smooth muscle cells [32]. 
These findings suggest that CArG elements play a central role in regulating 
smooth muscle gene expression, however these elements alone cannot explain 
the unique expression patterns of genes within different smooth muscle tissues. It 
is likely that different genes may require distinct additional factors to direct 
expression in different smooth muscle tissues. One of the goals of my thesis was 
to identify these additional elements within the telokin promoter. 
 
In addition to its important role in smooth muscle development, SRF also controls 
expression of cardiac and skeletal muscle-specific genes as well as genes 
involved in growth and proliferation. SRFʼs ability to regulate this disparate group 
of genes is regulated through several mechanisms such as regulated SRF 
expression levels, altered DNA binding or alternative splicing of SRF and 
association with cell-restricted cofactors [37]. For example SRFʼs interaction with 
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the myocardin family of cofactors allows it to potently activate smooth muscle-
specific genes selectively [50, 51]. Whereas SRFʼs interaction with the ETS 
family of cofactors allow it to selectively activate growth and proliferation genes 
[37]. Although selective cofactor interactions can at least partly explain the gene 
specificity of SRF these interactions still do not explain the unique tissue 
distribution of genes in distinct smooth muscle tissues. 
  
 
Approaches to generate transgenic mice for smooth muscle promoter 
analysis 
 
To understand the mechanisms regulating expression of genes in distinct smooth 
muscle tissues, it is necessary to analyze cis-acting regulatory elements and their 
role in regulating expression of these genes in vivo. Previously we and other labs 
have analyzed the activity of smooth muscle-specific promoters in transgenic 
mice in vivo by utilizing standard transgenic approaches. In this procedure the 
transgene construct is injected into pronucleus of a fertilized egg where it 
randomly integrates into the genome at a variable copy number. The expression 
pattern and level of these transgenes is dependant on copy number of the 
transgene and the chromatin structure at the site of integration leading to 
significant variability in the patterns and levels of expression in different founder 
lines [52]. Depending on the site of integration one can observe ectopic non-
specific expression due to the activity of nearby promoters or silencing of 
expression due to nearby silencer elements. For example, during our analysis of 
telokin promoter transgenes, we observed that the majority of transgenic lines 
exhibited no detectable transgene expression [33]. In addition, the pattern of 
transgene expression driven by an SM22α promoter was distinct in different 
transgenic lines, with most lines exhibiting artery-specific expression, whereas 
some showed additional expression in veins and in heart [33]. Variability in the 
expression patterns of these founder lines can make analysis of cis-acting 
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elements within these promoters difficult. Although generation of these 
transgenes is relatively fast it requires analysis of large numbers of independent 
founder lines. To be able to determine the relative importance of regulatory 
elements in different smooth muscle tissues, it is necessary to generate 
transgenic mice in which the activity of wild-type promoters are highly 
reproducible in terms of both their levels and tissue-specific patterns of activity. 
One way to improve transgene expression is to place insulator elements around 
the transgene. Although constructs still integrate randomly, with variable copy 
number, the insulator element protects the transgene from the effects of 
exogenous enhancers and silencers leading to more reproducible expression 
pattern. Studies have shown that insulator from H19 gene can be used for 
transgene studies [53, 54]. A second approach to minimize variability of 
transgene expression is to target single copy transgenes to a specific region of 
open chromatin structure by placing it adjacent to a housekeeping gene, such as 
hypoxanthine phosphoribosyltransferase (Hprt) [55]. Although this approach has 
previously not been utilized for smooth muscle-specific promoters, previous 
studies using endothelial cell-specific promoters demonstrated that, when 
targeted to this locus, these promoters exhibit very reproducible endothelium-
specific expression [56-59]. Similarly, the myogenin promoter also exhibited 
appropriate skeletal muscle-specific expression when targeted to the Hprt locus 
[60]. In this method mutated ES cells with a partial Hprt locus deletion are 
transfected with a targeting construct containing a LACz reporter gene and 
homology arms complementary to the Hprt locus [52, 61]. When homologous 
recombination occurs it restores Hprt function and cells can be selected by 
hypoxanthine-aminopterin-thymidine (HAT) media. The advantage using this 
approach is that it avoids the necessity of introduction of selectable markers. The 
HAT selection is very efficient with more than 80% of selected cells usually 
exhibiting the correct integration of the transgene. In my thesis studies I have 
utilized this approach to identify key regulatory regions and elements within the 
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telokin promoter that are required for expression in different smooth muscle 
tissues. 
 
 
Colon smooth muscle in diabetes 
 
Smooth muscle phenotypic changes occur during the development of 
atherosclerosis, asthma, and bladder and GI obstruction. In atherosclerotic 
plaques dedifferentiated smooth muscle cells exhibit a proliferative and synthetic 
phenotype. SM α-actin, MHC, calponin and SM22α genes are highly expressed 
in differentiated cells while they are downregulated in dedifferentiated 
atherosclerotic smooth muscle [62]. Smooth muscle contractile gene expression 
is also altered in asthma and diseases involving visceral smooth muscle 
obstruction where these genes are downregulated and in some cases distinct 
nonmuscle isoforms of the genes are expressed [63-66]. These disease-related 
phenotypic changes in different tissues lead to decreased contractility. Although 
diabetes has been shown to affect GI motility, whether it occurs through smooth 
muscle phenotypic changes have not been studied. In my thesis work I was 
interested to investigate the effects of diabetes on colon smooth muscle and 
determine whether altered GI motility occurs through mechanisms leading to 
smooth muscle dedifferentiation.    
 
 
Diabetes overview 
 
Based on data from the Center for Disease Control and Prevention, 23.6 million 
people (7.8%) in United States have diabetes. The two main types of diabetes 
are type 1 and type 2 diabetes. Type 1 diabetes is an autoimmune disease 
triggered by genetic and environmental factors leading to destruction of insulin 
producing β-cells resulting in impaired or abolished insulin secretion and 
15 
hyperglycemia. Approximately 50% of the genetic risk for type 1 diabetes is 
attributed to the human leukocyte antigen (HLA) region. Islet cell auto-
antibodies (ICA), antibodies to insulin (IAA), glutamic acid decarboxylase (GAA) 
and protein tyrosine phosphatase (IA2) have all been implicated in the 
development of type 1 diabetes [67]. A combination of many genes rather than 
a singe gene play a role in development of the disease, thus it is a polygenic 
disease which accounts for about 5% of all cases of diabetes.  
 
Type 2 diabetes is a metabolic disorder and occurs because of insulin resistance. 
Unknown primary defects leading to insulin resistance in metabolic tissues cause 
elevated blood glucose. In response to this elevated blood glucose the body 
increases insulin production in an attempt decrease glucose levels [68]. Thus, 
early stage of type 2 diabetes is marked with hyperglycemia and 
hyperinsulinemia. In the later stages, insulin levels are reduced because of β-cell 
depletion, and blood glucose levels are elevated. Risk factors for type 2 diabetes 
include obesity, genetic predisposition, physical inactivity, and impaired glucose 
metabolism. Type 2 diabetes can develop over a long period of time from a 
preclinical insulin resistance to a more significant insulin resistance that is 
associated with, hypertension, dislipidema and being overweight (metabolic 
syndrome) to full blown diabetes associated with β-cell failure. Type 2 is the most 
common and increasing form of diabetes and accounts for 90% of all diabetes 
cases. Therapy for type 2 diabetes is usually tailored toward obtaining glycemic 
control at each stage of the disease. Important step in prevention of 
complications of type 1 and type 2 diabetes is maintenance of normal glucose 
levels. The consequences of uncontrolled diabetes and persistent high glucose 
levels include peripheral neuropathy, cardiovascular and kidney disease and 
gastrointestinal motility problems [69-73].  
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Diabetes effects on the GI tract 
 
As many as 76% of diabetic patients at some point in the course of their disease 
develop gastrointestinal (GI) symptoms [74]. The entire GI tract motility from 
esophagus to anorectal area is affected by diabetes (Figure 4). Common 
symptoms in diabetic patients include dysphagia, gastroparesis, vomiting, early 
satiety, abdominal pain, constipation, diarrhea or fecal incontinence [74]. 
Constipation and gastroparesis are the most common symptoms and affect 
approximately 60% and 30-60% of the diabetic patients, respectively [74, 75].  
 
Gastroparesis is a condition where food is retained in the stomach because of 
decreased stomach motility. It leads to bloating, feeling of early satiety, 
abdominal pain, nausea and vomiting. Diabetic patients also develop small and 
large intestine motility problems leading to abnormal motility, impaired intestinal 
secretion or absorption problems [74]. These defects also lead to abdominal 
bloating, diarrhea or constipation. GI complications are mostly related and 
studied in respect to neuronal damage leading to neuropathy. Gastrointestinal 
neuropathies are known to affect GI tract motility, sensation, secretion and 
absorption. Different autonomic neurons stimulate or inhibit GI motility in different 
regions of the GI tract and neuropathies can lead to accelerated or delayed 
motility depending on which neurons are most affected. Study of diabetic patients 
have shown enlarged dystrophic axons and nerve terminals in prevertebral 
superior mesenteric (SMG) and celiac sympathetic ganglia (CG) [76]. Animal 
models of streptozotocin (STZ)-induced diabetes and diabetic BBW rats also 
show dystrophic axons of prevertebral sympathetic ganglia innervating the small 
intestine [77]. Recent study show that non-obese diabetic (NOD) mice also 
develop swollen axons and dendrites in the prevertebral superior mesenteric and 
celiac ganglia (SMG-CG) while STZ-induced diabetic mice developed less severe 
changes even after longer periods of time [78].  
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There is emerging evidence that the intrinsic ENS also play a role in diabetic 
neuropathy [78-83]. For example, STZ-induced diabetic rats show decreased 
number of enteric neurons in colon and stomach after only 7 days of 
hyperglycemia [84, 85]. Recent evidence also suggests that disrupted 
insulin/(insulin-like growth factor) IGF1 signaling might play a role in ENS 
apoptosis causing motility problems [86, 87]. Decreases in number and 
alterations in structure of ICC, (the pacemaker cells in the intestine) have also 
been observed in patients as well in different parts of the gastrointestinal tract 
of mice and rats with type 1 and type 2 diabetes [79, 82, 88, 89]. These 
changes have been associated with dysrhythmias and motility problems of 
gastrointestinal tract suggesting the role of the ENS and the pacemaker 
network in development of disease [90]. The loss of ICC has mostly been 
attributed to hyperglycemia [86, 87]. Although diabetic GI dysmotility often is 
associated with neuronal damage studies suggest that it is most likely a 
multifactorial disease also involving direct defects in smooth muscle and 
epithelial cells. Studies have shown that diabetes can lead to distinct smooth 
muscle alterations depending on the animal model used and the specific parts of 
the GI tract tested. Studies in an STZ-induced diabetic rat model revealed 
increased small intestine smooth muscle mass [91, 92]. The diabetic small 
intestine was longer with increased diameter when compared to control animals, 
although these changes did not affect contractile response to cholinergic 
stimulation. Other studies have shown increased colon contractility in rats [91, 
92]. In diabetic rats the frequency of spontaneous contractions in the colon was 
not affected while the amplitude was increased. Conversely in STZ-induced 
diabetic mice the smooth muscle contractile response to carbachol in colon was 
weaker when compared to control animals at 4 and 8 weeks following STZ 
treatment [93]. This was also associated with delayed gastric emptying and 
increased intestinal transit time [86]. Diabetic db/db mice with leptin receptor 
activity deficientcy also show lower gastric emptying and prolonged whole gut 
transit time as compared to wild type mice [79]. These studies together with the 
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hypercontractile and hypocontractile defects seen in human patients highlight the 
differing effects of diabetes on the GI tract.  
 
The molecular mechanisms leading to these different pathologies in GI smooth 
muscle of diabetic patients and animals are complex and are not well described. 
Altered GI contractility has been associated with altered calcium signaling. 
Studies in diabetic rats showed decreased intracellular Ca2+ handling in ileum but 
found no changes in colon [94]. Studies showing impaired smooth muscle 
contractility in the stomach of STZ-induced and db/db mice demonstrated that 
these changes were due to alterations in muscarinic receptor coupling through 
Guanosine-5'-triphosphate (GTP)-binding proteins [95]. Diabetic BB/W rats show 
no changes in KCl induced contractile responses compared to control animals, 
indicating that there are likely no defects in voltage gated L-type calcium 
channels in these animals. In contrast, a decreased contractile response of 
stomach smooth muscle that resulted from altered intracellular signal 
transduction through IP3 and PKC pathways was observed in these animals. 
[96]. In some severe cases of gastroparesis with poor glycemic control, 
dysmotility is associated with gastric smooth muscle myopathy [96, 97]. Diabetic 
patients with type 1 diabetes show atrophic smooth muscle cells and increased 
collagen production in muscularis propria layer likely related to the absence of 
insulin signaling [96, 97]. Diabetes related GI symptoms have been largely linked 
to hyperglycemia. Poor glycemic control rather than the duration of the disease 
seems to be associated with more severe GI problems [98]. However, recently it 
has been shown that that reduction in insulin/IGF-I in diabetic mice causes 
decreased stem cell factor (SCF) production and smooth muscle atrophy that 
eventually leads to ICC depletion [87]. These studies stress that myopathy may 
play a more central role in diabetic gastroenteropathies than previously 
recognized. It also emphasizes the role of insulin depletion rather than 
hyperglycemia in progression of the smooth muscle dysfunction. 
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Posttranslational protein modifications and contractility  
 
High glucose and oxidative stress lead to many diabetes related complications 
because of increased free radical formation. These changes can lead to 
posttranslational modification of proteins altering their physiological function 
through several different pathways. Two well recognized posttranslational 
modifications related to diabetes are O-linked glycosylation (O-glycosylation) and 
nitration. These modifications also have been shown to alter muscle contractility. 
Glucose mostly is metabolized through glycolysis; however, when there is a 
glucose overload it can also be metabolized via the hexosamine biosynthesis 
pathway (HBP). The end product of this pathway is uridine diphosphate N-acetyl-
glucosamine (UDP-GlcNAc), which is a substrate for protein O-glycosylation (O-
(GlcNAc-modification) on serine and threonine residues. Hyperglycemia and 
oxidative stress lead to increased levels of UDP-GlcNAc and elevated O-
glycosylation of nuclear, cytoplasmic and membrane proteins. O-glycosylation is 
a posttranslational modification that has been implicated in development of 
diabetic complications. Many transcription factors, cytoskeletal proteins, nuclear 
pore and signal transduction molecules are known to be O-glycosylated [99, 
100]. Moreover, diabetes have been shown to contribute to complications of 
diabetes in many tissues, including pancreatic β-cells, cardiomyocytes and 
skeletal muscle [101-104]. Although O-glycosylation can alter protein function in 
several ways one effect it has is to prevent the modified site from being 
phosphorylated [99]. Increased global O-glycosylation in cardiac and skeletal 
muscles have been shown to decreased Ca2+ sensitivity in these tissues and 
alter contractility [101, 102, 104]. This occurred through increased O-
glycosylation of the microfilaments thus leading to altered contractility. Although 
O-glycosylation has been shown to affect cardiac and skeletal muscle 
contractility, itʼs effects on contractility have not been explored in regard to colon 
smooth muscle in STZ-induced diabetic animals.  
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Nitration of tyrosine on different functionally important proteins is implicated in 
pathophysiology of many diseases such as Alzheimerʼs, Parkinsonʼs, endothelial 
dysfunction, inflammatory bowel disease (IBD) and diabetes [105-110]. Studies 
show that nitration of tyrosine residues can affect protein function by preventing 
these residues from being phosphorylated. Nitric oxide (NO) production in cells is 
regulated by enzymes neuronal NOS (nNOS), endothelial (eNOS) and inducible 
NOS (iNos). High iNos production occurs in an oxidative environment and once 
induced can produce large amounts of NO. In an oxidative environment, such as 
diabetes, NO can interact with superoxide (O2-) to form peroxynitrite (ONOO-) 
leading to nitration of tyrosine residues [111]. Studies in experimental colitis have 
shown that nitration attenuates L-type channel function in colon smooth muscle 
leading to decreased calcium influx into the cell and decreased contractility [112]. 
This study showed that L-type calcium channel mRNA and protein levels were 
not changed while calcium influx was decreased due to L-type calcium channel 
nitration and its subsequent inability to interact with c-src tyrosine kinase (c-Src) 
[113]. 
 
 
Inflammation and contractility 
 
Recent studies in colitis and postoperative ileus models have indicated that 
inflammation can lead to decreased gut motility. It is believed that macrophages 
residing in the muscularis layer in gastrointestinal tract play a significant role in 
inflammatory response [114]. Studies using macrophage-deficient osteopetrotic 
mice showed decreased levels of pro-inflammatory cytokine release and 
improved gastrointestinal transit after postoperative ileus manipulation [115]. It 
have been shown that surgical manipulation activates macrophages by activating 
Mitogen-activated protein kinase (MAPK) signaling pathway resulting in 
activation of early growth response (Egr)-1, nuclear factor kappa B (NFκ-B) and 
interleukin (IL)-6 [116-118]. These signaling pathways lead to secretion of pro-
21 
inflammatory cytokines tumor necrosis factor (TNF) α, IL-1, IL-6 as well as NO 
and cyclooxygenase (COX)-2 production in macrophages of the muscular layer 
[116-118]. Further studies showed that direct TNFα treatment decrease 
gastrointestinal smooth muscle contractility [117]. iNos knockout mice also 
showed decreased neutrophil infiltration in muscularis after intestinal 
manipulation and normal contractile response when compared to the attenuated 
response seen in wild type animals. These studies suggest that iNos can play an 
important role in inhibiting GI smooth muscle contractility [119]. Studies using 
bone marrow transplants from iNOS KO mice suggest that the biologically 
important iNOS that attenuates contractility after surgical manipulation is derived 
from blood cells [120]. These data highlight the importance of macrophages at 
the first steps of inflammation-induced impairments in GI smooth muscle 
contractility. 
 
 
Thesis Rationale 
 
The overall goal of my study was to identify molecular mechanisms that regulate 
gene expression specifically in GI smooth muscle cells and determine how these 
mechanisms are altered under pathological conditions. As the smooth muscle 
contractile regulatory protein telokin is highly and specifically expressed in 
visceral smooth muscle in vivo, I utilized this gene to dissect the transcriptional 
pathways that control gene expression in GI smooth muscle. Specifically I set out 
to determine whether Hprt-targeted transgenes would give reproducible 
transgene expression patterns suitable for the analysis of cis-acting gene 
regulatory elements.  
 
As diabetes have been shown to affect GI tract motility in human patients and 
animal models the second goal of my studies was to determine whether colon 
smooth muscle undergoes dedifferentiation in a mouse model of type 1 diabetes. 
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As part of this goal I examined the effects of diabetes on colon smooth muscle 
contractility. Previous studies in diabetic rats implied that altered GI contractility 
possibly occurs through altered sensitivity to calcium in smooth muscle [94]. As 
telokin is known to play a role in smooth muscle calcium desensitization, the 
other part of my goal was to determine whether telokin expression is altered in 
colon smooth muscle of diabetic mice.  
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 Figure 1. Layers of the colon. The colon is lined with mucosa layer consisting 
of epithelial cell layer, lamina propria and muscularis mucosae. The mucosa layer 
forms invaginations called villi that are supplied with glands and contain lymphoid 
nodules. The next is the submucosa layer located between mucosa and smooth 
muscle layers. The outer muscle layer muscularis externa consists of inner 
circular layer and outer longitudinal layer. The outermost layer is the serosa. The 
nervous Meissnerʼs plexus is located between muscularis mucosae and 
submucosa. Another nervous Auerbachʼs plexus is located between two smooth 
muscle layers. Mesenteric vessels reach the wall of the colon for blood supply.  
Ross and Romrell, Hystology. A text and atlas. Second edition, 1989.  
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 Figure 2. Channels and receptors involved in colon smooth muscle 
calcium signaling. L-type cannels (Cav1.2) and TRP channels are located in the 
cell membrane and are involved in calcium influx. PMCA and NCX are 
transporters located in the plasma membrane and play roles in calcium export 
out of the cell. IP3R is located on the membrane of SR and triggers calcium 
release from SR. RyR are also located on SR and play role in calcium-induced 
calcium release (CICR). SERCA is Ca ATP-ase located on the SR and plays role 
in the calcium uptake to SR and smooth muscle relaxation. SERCA activity is 
regulated by phopspholamban (PLB). PLB binding to SERCA inhibits calcium 
uptake while PLB release activates calcium uptake into SR. 
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 Figure 3. Structure of the mouse mylk1 gene, mylk1 transcripts and 
minimal telokin promoter schematics. (A) Representation of a portion of the 
mouse mylk1 gene. Exons are indicated by boxes and are color coded to match 
the domains in the (B) schematics. The dark gray boxes represent the unique 5'-
untranslated region (UTR) segments of each transcript. Promoter regions are 
indicated by the blue boxes below the line. Genomic sequence predicts that two 
5' promoters direct the expression of the two isoforms of the 220-kDa MLCK that 
differ from each other only in the sequence encoded by exon 1* of the 220-kDa 
MLCK E1*. The protein produced from usage of exon 1* is predicted to be 9 
amino acids longer than the protein resulting from usage of exon 1. Two internal 
A 
 
 
 
 
 
B 
 
 
 
 
 
 
C 
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promoters direct the expression of transcripts encoding the 130-kDa MLCK and 
telokin. (B) Representation of the mylk1 transcripts. The amino acid sequence of 
telokin is identical to the COOH terminus of the MLCK molecules. The amino acid 
sequence of the 130-kDa MLCK is identical to the common COOH-terminal 
portion of the 220-kDa MLCK. (C) Telokin minimal promoter schematics. 
Numbers assigned are relative to transcription start stite. Analysis of promoter 
fragments in transgenic mice has suggested that the core of the telokin promoter, 
which includes a CArG box and adjacent AT-rich region, is required for 
expression in smooth muscle cells. 
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 Figure 4. Diabetes-related defects of gastrointestinal tract. Type 1 and type 
2 diabetes leads to defective motility in upper and lower GI tract. Diabetic 
patients develop dysmotility of the esophagus, stomach and intestine.  
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CHAPTER II 
 
HPRT-TARGETED TRANSGENES PROVIDE NEW INSIGHTS INTO SMOOTH 
MUSCLE-RESTRICTED PROMOTER ACTIVITY 
 
Summary 
 
Mouse telokin and SM22α promoters have previously been shown to direct 
smooth muscle cell-specific expression of transgenes in vivo in adult mice. 
However, the activity of these promoters is highly dependent on the integration 
site of the transgene. In the current study, we found that although the ectopic 
expression of these transgenes could be abolished by flanking the transgene with 
insulator elements from the H19 gene. However, the insulator elements did not 
increase the proportion of mouse lines that exhibited consistent, detectable levels 
of transgene expression. In contrast, when transgenes were targeted to the Hprt 
locus both telokin and SM22α promoters resulted in reproducible patterns and 
levels of transgene expression in all lines of mice examined. Telokin promoter 
transgene expression was restricted to smooth muscle tissues in adult and 
embryonic mice. As reported previously, SM22α transgenes were expressed at 
high levels specifically in arterial smooth muscle cells; however, in contrast to 
randomly integrated transgenes, the Hprt-targeted SM22α transgenes were also 
expressed at high levels in smooth muscle cells in veins, bladder and 
gallbladder. Using Hprt-targeted transgenes we further analyzed elements within 
the telokin promoter required for tissue specific activity in vivo. Analysis of these 
transgenes revealed that the CArG element in the telokin promoter is required for 
promoter activity in all tissues and that the CArG element and adjacent AT-rich 
region are sufficient to drive transgene expression in bladder, but not intestinal 
smooth muscle cells. 
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Introduction 
 
Analysis of transgene expression driven by various fragments of smooth muscle-
specific promoters has suggested that distinct cis-acting regulatory elements are 
required to direct expression of genes in different smooth muscle tissues [18, 20, 
33, 49, 121, 122]. It is thus likely that distinct transcription regulatory pathways 
control the expression of genes in different smooth muscle tissues. This 
hypothesis is supported by several observations; for example differentiation of 
coronary artery smooth muscle cells is dependent on a complex of SRF, 
GATA4/6 and CRP [123]. In contrast, differentiation of aortic smooth muscle cells 
is dependent on myocardin [124], whereas myocardin-related transcription factor 
B (MRTF-B) plays a specific role in the differentiation of cardiac neural crest-
derived smooth muscle cells [125, 126].  
 
To better understand the mechanisms regulating expression of genes in distinct 
smooth muscle tissues, it is necessary to carefully analyze the relative 
importance of individual cis-acting regulatory elements in regulating expression of 
these genes in each tissue in vivo. Previous studies that have analyzed the 
activity of smooth muscle-specific promoters, in transgenic mice in vivo, have 
utilized standard transgenic approaches. One of the limitations of this approach 
is that the site of integration of the transgene and the transgene copy number can 
greatly affect both the pattern and level of transgene expression. For example, in 
our analysis of telokin promoter transgenes, we observed that the majority of 
transgenic lines exhibited no detectable transgene expression [33]. In addition, 
the pattern of transgene expression driven by an SM22α promoter was distinct in 
different transgenic lines, with most lines exhibiting arterial-specific expression 
while some showed additional expression in veins and in heart [33]. In general, 
telokin promoter transgenes are expressed at highest levels in visceral smooth 
muscle tissues [33], by contrast, SM22α transgenes are most highly expressed in 
vascular smooth muscle tissues [18, 20, 122]. The reciprocal expression of 
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telokin and SM22α transgenes, make these two promoters good tools for 
identifying regulatory elements that direct transcription to distinct smooth muscle 
tissues. However, the variable patterns and levels of expression of these 
transgenes makes analysis of regulatory elements within these promoters 
difficult, requiring the analysis of large numbers of independent founder lines. In 
order to be able to determine the relative importance of regulatory elements in 
different smooth muscle tissues it is necessary to generate transgenic mice in 
which the activity of wild type promoters are highly reproducible both in terms of 
their levels and tissue-specific patterns of activity. 
 
In the current study we used two different approaches to decrease the variability 
in the pattern and level of transgene expression. In the first, we used a transgene 
cassette in which the transgene is flanked by insulator elements from the H19 
gene. In a second approach, we targeted single copy transgenes adjacent to the 
hypoxanthine phospho-ribosyltransferase (Hprt) locus using homologous 
recombination in ES cells. Hprt is a housekeeping gene expressed in all cell 
types, hence it would be anticipated that this locus would be transcriptionally 
favorable. Although this approach has not been utilized for smooth muscle-
specific promoters, previous studies using endothelial cell-specific promoters 
demonstrated that, when targeted to this locus, these promoters exhibit very 
reproducible endothelial-specific expression [56-59]. Similarly, the myogenin 
promoter also exhibited appropriate skeletal muscle-specific expression when 
targeted to the Hprt locus [60]. Results from the current studies demonstrate that 
telokin promoter-driven transgenes exhibited greatly reduced ectopic expression 
when flanked by insulator elements. However, the levels of transgene expression 
still remained highly variable between transgenic lines. In contrast, Hprt-targeted 
telokin promoter transgenes exhibited faithful, reproducible patterns and levels of 
transgene expression, in all animals examined. In Hprt-targeted telokin promoter 
transgenes, similar to endogenous telokin, expression was restricted to visceral 
and to a lesser extent vascular smooth muscle tissues. The reproducible patterns 
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and levels of transgene expression allowed us to begin to determine the 
importance of specific regulatory elements within the telokin promoter. We found 
that although mutation of the CArG box was sufficient to abolish transgene 
expression in all smooth muscle tissues, a core promoter extending from -90 to 
+180 relative to transcription start site, that included an AT-rich region and the 
CArG box, was not sufficient for high levels of transgene expression in most 
smooth muscle tissues. Analysis of Hprt-targeted SM22α promoter transgenes 
demonstrated that the Hprt-targeting system is universally applicable to smooth 
muscle-restricted promoters. These transgenes also exhibited a very 
reproducible pattern of transgene expression in all animals analyzed.  Hprt-
targeted SM22α transgenes were transiently expressed in embryonic skeletal 
and cardiac muscle and robustly expressed specifically in embryonic and adult 
arterial, venous and bladder smooth muscle tissues. 
 
 
Methods 
 
Transgenic mouse production. The 370bp telokin promoter-AUG LAC 
transgenes, contained the -180 to +190 fragment of the mouse telokin promoter 
fused to a modified b-galactosidase transgene, followed by an SV40 large T-
antigen polyadenylation sequence, as described previously [33]. To generate a 
transgene that is flanked by insulator elements, the 370bp mouse telokin 
promoter fragment extending from -180 to +190 relative to transcription start site 
was amplified by PCR, digested with XhoI and ligated into the pWhere vector 
(InvivoGen, San Diego, CA). Restriction digestion and DNA sequencing were 
performed to confirm the orientation and integrity of the resultant plasmid such 
that the promoter is located in the 5ʼ-3ʼ orientation 5ʼ of a modified LACz gene in 
which all CpG sequences are mutated and a SV40 nuclear localization added 
(T370-pWhere). The Indiana University Transgenic Facility generated all 
standard transgenic lines in C3H mice; founders were then bred with DBA/2 mice 
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to establish stable lines. Transgenic animals were identified by PCR. To generate 
Hprt-targeted transgenes, telokin promoter fragments extending from -190 to 
+180 (T370), -90 to +180 (T270), a -180 to +190 telokin promoter harboring a 
mutation in the CArG element and a -475 to +61 SM22α promoter were cloned 
into the AUG-LAC β-galactosidase vector. The AUG-LAC transgene vectors, 
were then digested with appropriate restriction enzymes and cloned into the 
pMP8SKB Hprt targeting vector, kindly provided by Dr. Sara Bronson [55]. This 
resulted in the placement of the promoter, LAC cDNA and SV40 poly A sequence 
5ʼ of the Hprt promoter (Figure 5). The resultant targeting constructs were 
linearized by digestion with Sal I and electroporated into BK4 embryonic stem 
cells by the Indiana University Transgenic Mouse facility [55]. Correctly targeted 
embryonic stem cells have repaired the mutant Hprt gene in BK4 ES cells and 
can therefore be selected using HAT media. HAT resistant clones were 
expanded and genomic DNA isolated (Puregene, Gentra Systems, Minneapolis, 
MN). Homologous recombination was then confirmed by southern blot analysis of 
genomic DNA digested with Bam HI. Wild type BK4 cells have a 9kb Bam HI 
fragment, that hybridizes to an exon 3 derived probe, whereas cells harboring the 
targeted telokin transgene have an approximately 12kb fragment (Figure 5). For 
all Hprt-targeted transgenes (except T370 AUG LAC, in which chimeras derived 
from only 1 ES line transmitted the transgene) lines of mice were established 
from two independently targeted ES clones. As the Hprt gene is on the X 
chromosome, transgene expression was analyzed in hemizygous male mice or in 
homozygous female mice.  
 
Transgenic mice were genotyped by PCR using transgene specific primers. 
Primers used were: Telokin 370 AUG-LAC, Telokin 370-Hprt and Telokin 370 
CArG mutant-Hprt; S- ACTGTCTCTTTGACCACTTGAAATCC, AS- 
GGCAGGGTTTTCCCAGTCACGACG TTG; Telokin 370-pWhere S, same as 
T370 AUG-LAC, and AS- CAACCCACCTG CCATTGCACCAGAGGTG; Telokin 
270-Hprt, S-GAAGTAGGCTAAAGAGTTGAACGCAAAG, AS- 
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GGCAGGGTTTTCCCAGTCACGACGTTG; SM22α-Hprt, S-GCACAGACTG 
CTCCAACTTGGTGTCTTTC, AS-CAACCCACCTGCCATTGCACCAGAGGTG. 
Male embryos were identified by using PCR primers S-
GTACAAGTCTGCAGACTCTTCCAAC and AS-
CCGAGGGTCTCCGGAATCCTTTCTTG that were designed to amplify the ZFY 
region on the Y chromosome. 
   
β-galactosidase staining and histology. For whole mount analysis of β-
galactosidase expression in neonatal F1 mice and adult founder mice, tissues 
were rapidly excised and fixed for one hour on ice in 2% paraformaldehyde/ 0.2% 
gluteraldehyde in phosphate buffered saline (PBS). For analysis of expression in 
whole embryos, embryos were dissected free of the yolk sac and then treated as 
described for tissues. Following fixation, tissues or embryos were washed 4-6 
times with PBS and stained with X-gal staining solution overnight at room 
temperature. X-gal staining solution is comprised of 0.5mg/ml X-Gal, 5mM 
K3Fe(CN)6, 5mM K3Fe(CN)6, 2mM MgCl2, 0.2% NP40, 0.2%Tween 20, 
0.2%Triton X-100 in PBS. Tissues are then washed in PBS and further fixed in 
4.0% paraformaldehyde overnight. Following fixation, tissues were either directly 
photographed using a dissecting microscope and digital camera (Kodak 
MDS290) or were dehydrated in increasing concentrations of ethanol and cleared 
in methyl salicylate prior to photography. Tissues for histological sections were 
excised, equilibrated in 20% sucrose in PBS overnight, frozen in tissue freezing 
medium (Triangle Biomedical Sciences) and sectioned at 8-12µm.  For analysis 
of b-galactosidase expression slides were fixed in 0.5% gluteraldehyde in PBS 
for 10 minutes at room temperature, washed in PBS, stained overnight with X-gal 
staining solution, washed 3 times in PBS and then counterstained with 
Hematoxylin and Eosin according to standard procedures. For analysis of smooth 
muscle myosin expression, sections were fixed in 3.7% formaldehyde and 
incubated with antibodies directed against SM1 smooth muscle myosin heavy 
34 
chain, primary antibody was detected using fluorescein conjugated anti-rabbit 
IgG, as described previously [127]. 
 
 
Results 
 
Addition of insulator elements decreases ectopic expression of transgenes 
driven by the telokin promoter in embryos. Previously we have shown that a 
370bp mouse telokin promoter fragment can direct β-galactosidase expression 
specifically to smooth muscle tissues in neonatal and adult mice [33]. However, 
only 4 out of 14 lines of transgenic mice harboring this transgene had detectable 
levels of transgene expression. In addition, we observed significant ectopic 
expression of the transgene at embryonic days 12.5 and 14.5 in these mice 
(Table 1 and data not shown). To determine if the ectopic expression of telokin 
promoter-driven transgenes during embryonic development results from the 
influence of exogenous enhancer elements, transgenic mice were generated in 
which the transgene was flanked by insulator elements (Methods). Of the 6 
positive transgenic lines obtained using this transgene cassette, only three lines 
had detectable levels of β-galactosidase expression. In one of these three lines 
(line #3) expression levels were very low with only a few smooth muscle cells 
staining in the gut and bladder (Table 1). The other two lines (lines #1,2) showed 
robust β-galactosidase staining that was restricted to smooth muscle cells of the 
gastrointestinal, genitourinary and respiratory tracts, in adult mice (Table 1). Low 
levels of expression were also observed in the abdominal aorta and mesenteric 
vessels. There was no detectable β-galactosidase expression in the aortic arch, 
coronary or pulmonary vasculature, in the brain, cardiac muscle or any other 
tissue examined (including liver, kidney and skeletal muscle, data not shown). 
Only one of these lines (#1) passed the transgene to the F1 generation, 
permitting analysis of embryonic expression. In embryos from this line, transgene 
expression was restricted to smooth muscle cells (Table 1). This pattern of 
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expression mimics endogenous telokin, which is also restricted to smooth muscle 
cells throughout development. 
 
Hprt-targeted transgenes recapitulate endogenous telokin expression in 
adult mice and during embryonic development. As addition of insulator 
elements did not lead to increased numbers of mice exhibiting detectable levels 
of transgene expression, we next targeted transgenes to the X-linked  
hypoxanthine phosphoribosyltransferase (Hprt) locus. Hprt is a housekeeping 
gene expressed in all cell types, hence it would be anticipated that this locus 
would be transcriptionally favorable. The 370bp AUG-LAC transgene, described 
previously [33], was introduced into the Hprt targeting vector pMP8SKB as shown 
in Figure 5. Six chimeric male mice were generated from a telokin promoter 
transgene ES clone (clone #6, Figure 5), and bred with C57/BL6J female mice. 
Five of these chimeras transmitted the transgene, three were used to establish 
transgenic lines. Four male hemizygous animals (F2-4) were analyzed from each 
line. To obtain homozygous transgenic female mice, hemizygous male mice were 
bred with heterozygous transgenic females. In all mice analyzed, β-galactosidase 
was expressed at high levels in visceral smooth muscle cells throughout the GI 
tract, bladder and bronchi. Low levels of expression were seen in gallbladder, 
vascular smooth muscle cells of mesenteric vessels, in vessels on the surface of 
the brain, in the abdominal aorta, vena cava and in the renal vessels (Figure 6, 
Table 2). No transgene expression was detected in the thoracic aorta, pulmonary 
or coronary vasculature or in any other tissue, such as heart, skeletal muscle, 
liver or kidney. Within these tissues transgene expression was restricted to 
smooth muscle cells (Figure 6 and data not shown). The pattern of expression of 
this transgene mirrors that of endogenous telokin, which is expressed at high 
levels in visceral smooth muscle tissues and lower levels in vascular smooth 
muscle (Table 2 and references 5,14). In contrast to endogenous telokin and 
transgene expression in T370 AUG-LAC and T370 pWhere mice, no β-
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galactosidase activity was detected in the reproductive tract smooth muscle of 
the Hprt-targeted mice.  
 
The smooth muscle-specific pattern of transgene expression in T370-Hprt mice 
was maintained throughout embryonic development. Expression was first 
detected at E11.5 in the umbilical artery (Figure 7). By day 12.5 expression could 
also be seen in the intestine and in a small group of cells at the apex of the heart. 
In E14.5 mice, robust expression was seen in the herniated gut and umbilical 
artery and lower levels of expression could be seen in the bronchi, abdominal 
aorta, cerebral vasculature and at the apex of the heart (Figure 7). In sections 
obtained from E14.5 and E15.5 mice β-galactosidase expression was shown to 
be restricted to the smooth muscle cells in the bladder, gut and umbilical vessels 
(Figure 7 and data not shown). We were not able to detect the β-galactosidase 
positive cells at the apex of the heart in histological sections, hence the identity of 
these cells could not be determined. 
 
Hprt-targeted SM22α-promoter driven transgenes are expressed in venous 
and bladder smooth muscle cells in addition to arterial smooth muscle 
cells. To determine if the Hprt-targeting system would be generally applicable to 
other smooth muscle- specific promoters we also generated and characterized 
Hprt transgenes driven by a -475 to +61 fragment of the SM22α promoter. 
Previously, we noted that transgenes driven by this SM22α promoter also 
exhibited variable patterns of expression in different lines of mice [33]. In all of 
the Hprt-targeted SM22α promoter-driven transgenic mice, derived from two 
independent ES clones, we observed an identical pattern of transgene 
expression. High levels of β-galactosidase activity were detected in arteries and 
veins in small and large blood vessels, including mesenteric, abdominal, renal, 
thoracic, pulmonary, coronary, femoral and brain vasculature. Little or no staining 
was observed in visceral smooth muscle tissues except in the bladder and 
gallbladder, which exhibited high levels of β-galactosidase activity (Figure 8, 
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Table 2).  Some staining was also observed in the main branches of bronchi at 
the entrance to the lung, but was not detected in trachea or further along the 
bronchi or bronchioles. In E12.5 mice we observed strong β-galactosidase 
staining in dorsal aorta, umbilical artery and vein, vitelline vessels, heart and 
somites. By E14.5 expression in heart and somites had declined and expression 
in small blood vessels throughout the head and limbs increased (Figure 9). 
 
Cis-acting elements located 5ʼ of the AT-rich/CArG core of the mouse 
telokin promoter are necessary for driving expression in GI smooth muscle 
cells. Previously, we showed that the -94 to -49 core of the telokin promoter, that 
includes an AT-rich region and CArG box, is required for telokin transcription in 
vivo [22]. To determine if this region is sufficient to drive telokin promoter activity, 
an Hprt-targeted transgene was generated containing a fragment of the telokin 
promoter extending from -90 to +180. In all neonatal mice harboring this 
transgene there was almost no transgene expression detected in intestinal 
smooth muscle cells (Figure 10, Table 2). Although expression in bladder smooth 
muscle cells was also reduced, as compared to expression in transgenes driven 
by the larger -190 to +180 telokin promoter fragment, (compare Figure 2 to 
Figure 10) it remained significantly higher than in intestinal smooth muscle cells 
(Figure 10). Expression levels in mesenteric, renal and brain vasculature also 
decreased slightly, and expression in bronchi, abdominal aorta and vena cava 
was not detectable.  
 
The CArG box in the mouse telokin promoter is required for telokin 
promoter activity in all smooth muscle tissues. Our previous in vitro results 
suggest that a CArG element is crucial for telokin promoter activity [32]. In 
addition, deletion of the CArG element together with the adjacent AT-rich region 
abolished the activity of the endogenous telokin promoter [22]. To determine if 
CArG element alone is required for telokin promoter activity this element was 
mutated to ablate SRF binding within the context of the 370bp, -190 to +180 
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telokin promoter. Two lines of Hprt-targeted transgenes were generated from 
independently targeted ES clones. In all adult and embryonic mice harboring this 
transgene no specific β-galactosidase expression was detected in any tissue 
(Table 2).  
 
 
Discussion 
 
These results demonstrate that a single copy of the telokin promoter targeted to 
the Hprt locus is able to reproducibly drive high levels of transgene expression 
specifically in smooth muscle tissues throughout mouse development. Most 
importantly, the pattern of expression of this transgene largely recapitulated the 
expression of the endogenous telokin. Although flanking telokin promoter driven 
transgenes with insulator elements abolished ectopic transgene expression, 50% 
of the lines of mice harboring these transgenes still did not exhibit detectable 
levels of transgene expression (Table 1). As the insulators should block the 
activity of repressor elements, the lack of expression in many lines may be due to 
the integration of the transgene at sites of compact, inactive chromatin. If 
transgenes integrate into sites of compact chromatin structure, then the activity of 
the transgene will depend on the ability of the regulatory elements within the 
transgene to modify chromatin structure, allowing appropriate transcription 
factors to bind and activate the promoter. All of the telokin promoter-driven 
transgenic lines, derived from a single ES clone in which the transgene was 
targeted to the Hprt locus, exhibited high levels of transgene expression. We also 
observed a similar pattern of expression when this promoter was used to drive 
expression of an EGFP transgene targeted to the Hprt locus (data not shown). 
Thus, when placed in a region of relaxed, open chromatin structure, such as the 
Hprt locus, the 370bp telokin promoter is able to mediate high levels of tissue-
restricted transgene expression. This then raises the question of how the telokin 
promoter is active in its endogenous location if it is not able to remodel chromatin 
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structure. The telokin gene locus is, however, rather unusual in that the telokin 
promoter is located within an intron of the larger mylk1 gene [16, 17, 131]. In 
addition to telokin, the mylk1 gene encodes at least two myosin light chain kinase 
(MLCK) isoforms, the 220kDa and 130kDa MLCK [131]. Each of these protein 
kinases is transcribed from its own independent promoter within the mylk1 gene, 
rather than arising from alternative splicing [131, 132]. Myosin light chain kinases 
are expressed in most if not all tissues in adult and embryonic mice [133], hence 
it would be anticipated that the MLCK/telokin locus would be expected to have a 
transcriptionally active, open chromatin configuration in most cells, throughout 
development. This proposal suggests that upstream elements in the mylk1 gene 
exist, that are responsible for maintaining the chromatin structure of the telokin 
promoter in a relatively open conformation. Further studies will be required to 
confirm this possibility. 
 
The visceral smooth muscle-selective pattern of expression of Hprt-targeted 
telokin promoter-driven transgenes parallels endogenous telokin expression. 
Both in adult and in embryonic mice, endogenous telokin is expressed at higher 
levels in most visceral smooth muscle tissues compared to vascular smooth 
muscle tissues [21, 31]. Hprt-targeted telokin promoter transgene expression was 
observed in cells on the surface of the apex of the heart in E12.5-E14.5 mice 
(Figure 7). This may reflect ectopic expression, resulting from an influence of the 
Hprt locus on the transgene, as endogenous telokin expression has not been 
observed in embryonic mouse heart [31]. However, as β-galactosidase 
expression in these cells is low and could not be detected in tissue sections, it is 
possible that expression of endogenous telokin in these cells may also not have 
been detected in our previous in situ hybridization study [31]. Our inability to 
detect β-galactosidase expression in these cells on tissue sections has 
prevented us from further characterizing these cells to determine their identity. In 
contrast to endogenous telokin, Hprt-targeted telokin promoter transgene 
expression was not observed in smooth muscles of the male or female 
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reproductive tract (Table 2). As both telokin promoter pWhere and AUG-LAC 
transgenes exhibit transgene expression in uterine smooth muscle (Table 1) this 
would suggest that the lack of expression of Hprt-targeted transgene expression 
in uterine smooth muscle most likely results from ectopic influences of the Hprt 
locus.  
 
Although previous studies have shown that SM22α promoter transgenes are 
restricted to arterial smooth muscle we also observed high levels of expression in 
bladder, gallbladder and veins when the transgene was targeted to the Hprt locus 
(Figure 8). Moreover, venous expression was observed not only in adult animals 
but also through embryonic development at E12.5 and E14.5 (Figure 9). Although 
the Hprt-targeted SM22α transgenes more closely recapitulate endogenous 
SM22α expression, which is expressed in all smooth muscle tissues [35, 129, 
134], the lack of transgene expression in GI and reproductive tract smooth 
muscle cells suggest that additional more distal regulatory elements are required 
to drive SM22α expression in these tissues. In support of this proposal, a BAC 
clone encompassing the SM22α gene was expressed in all smooth muscle 
tissues in transgenic mice [36]. The expression of the Hprt-targeted SM22α 
transgenes in bladder and veins also suggest that tissue-specific chromatin 
remodeling complexes may be important for regulating SM22α expression. 
Alternatively, it is possible that regulatory elements within the Hprt locus are 
affecting the activity of the SM22α promoter to increase expression in veins and 
bladder smooth muscle.  
  
The reproducible pattern of expression of telokin- and SM22α-driven transgenes 
targeted to the Hprt locus permitted us to begin to dissect the role of individual 
elements within these promoters. A telokin promoter fragment extending from -90 
to +180 exhibited a marked decrease in expression when compared to a -190 to 
+180 transgene (Figure 10). Transgene expression in the GI tract was 
41 
particularly affected with only a few isolated cells staining positive for β-
galactosidase activity (Figure 10). This result is in contrast to in vitro data in 
which deletion of the -190 to -94 region resulted in only a 30% decrease in 
reporter gene activity in A10 smooth muscle cells [33]. However, the small 
change in activity in A10 cells may reflect cell-specific differences, as the low 
levels of transgene expression seen in the vasculature did not appear to be as 
significantly affected by deletion of the -190 to -90 region as transgene 
expression in the GI tract (Figure 10). Together these data suggest that the -190 
to -90 region of the telokin promoter is required for high levels of telokin 
expression, and that this fragment is particularly important in smooth muscle cells 
of the GI tract. Although we do not yet know which transcription factors bind to 
this region, analysis of the sequence of the -190 to -90 region using rVISTA 
revealed the presence of a conserved Sox binding site. As Sox family members 
have been shown to play a role in GI tract development it is tempting to propose 
that they may be contributing to telokin expression in the GI tract [135].   
 
Previous studies have demonstrated that SRF binds to this CArG box in the 
telokin promoter, in intact chromatin, in smooth muscle cells and that myocardin 
can strongly activate the promoter through its interaction with SRF bound to this 
site [136]. Myocardin has been shown to be a powerful co-activator of SRF on 
smooth muscle specific genes and to be required for vascular smooth muscle 
development [50, 51, 124, 130, 137]. In the current study we have also shown 
that the CArG box is required for telokin expression in all smooth muscle tissues 
in vivo (Table 2). However, the CArG box and adjacent AT-rich region are not 
sufficient for telokin promoter activity in vivo, in most smooth muscle tissues, as a 
-90 to +180 telokin transgene was not expressed at significant levels in the GI 
tract, reproductive tract or in airway smooth muscle. Together these data suggest 
that, in these smooth muscle tissues, myocardin must cooperate with other 
factors to drive telokin expression.  
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In summary, the reproducibility of Hprt-targeted telokin and SM22α promoter 
transgene expression will greatly facilitate analysis of the tissue-specific roles of 
cis-acting elements within these promoters. The advantage of this approach, is 
that a single copy of the transgene integrates at a defined locus, this thus 
permits, quantitative comparison of transgene expression driven by wild type and 
mutant promoters. 
 
Further we were interested to investigate weather telokin transcriptional 
regulation is altered in disease state. Previous studies in diabetic rats showed 
that impaired GI contractility possibly occurs through altered sensitivity to calcium 
in colon smooth muscle [94]. As telokin is known to play a role in smooth muscle 
calcium desensitization, it could possibly play a role in motility defect detected in 
diabetic patients and animal models. Thus, I was interested to determine whether 
colon smooth muscle in diabeteic state undergoes dedifferentiation leading to 
decreased telokin expression. 
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Figure 5. Telokin promoter Hprt targeting scheme. (A) Schematic 
representation of the Hprt targeting vector. (B) Southern blot analysis of genomic 
DNA extracted from targeted HAT resistant embryonic stem cell clones. Genomic 
DNA was digested with BamHI, separated on a 0.8% agarose gel, transferred to 
a nylon membrane and then reacted with a probe to exon 3 of the mouse Hprt 
gene (shown in A). A 9 kb band corresponding to the endogenous mouse Hprt 
gene fragment was seen in wild type cells and bands of approximately 12 kb 
were seen in clones 2, 5 and 6 corresponding to the correctly targeted locus. The 
band obtained from clone #5 was slightly smaller than the bands obtained from 
clones 2 and 6, additional PCR and sequence analysis revealed that this clone 
contained a small deletion within the β-galactosidase cDNA. ES clones #2 and #6 
were used to generate chimeric mice. Chimeric mice derived from ES clone #2 
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did not transmit the transgene, hence data presented are from mice derived from 
ES clone #6. Clone #3 contained a band significantly larger than 12 kb and likely 
represents an insertional event rather than a replacement as described 
previously [55]. 
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Figure 6. Expression of Hprt-targeted telokin 370AUG-LAC transgenes in 
adult mice. Tissues were rapidly dissected from a positive hemizygous male 
Hprt-targeted telokin promoter 370bp AUG-LAC transgenic mouse, fixed and 
stained for β-galactosidase expression as described in ʻMethodsʼ. This transgene 
resulted in high levels of β-galactosidase expression in smooth muscle tissues of 
the bladder, colon, stomach, duodenum, bronchi (Br), trachea (Tr) and renal 
artery (RA) and low levels of expression in the abdominal aorta (aA), vena cava 
(V), ureter (Ur) but no expression in the aortic arch (AA) or thoracic aorta (tA) as 
indicated. In the bottom three panels tissues were frozen, and serial sections 
were stained for β-galactosidase (blue stain), hematoxylin and eosin (X-Gal/H&E) 
and smooth muscle myosin heavy chain (SM1, green). The arrows on the 
abdominal aorta section indicates β-galactosidase positive smooth muscle cells. 
The scale bars represent 100µm. 
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Figure 7. Expression of Hprt-targeted telokin (-190 to +180) transgenes 
during embryonic development. Timed embryos were obtained from Hprt-
targeted 370 bp telokin promoter (-190 to +180) AUG-LAC transgenic mice as 
indicated. Positive male mice were identified by PCR using transgene specific 
primers and primers to the ZFY locus which is located on the Y chromosome. 
Male embryos were processed for histochemical detection of β-galactosidase 
expression as described in ʻMethodsʼ. Blue staining representing β-galactosidase 
expression can be first seen at E11.5 in the umbilical artery (UA). This staining is 
more pronounced at E12.5 and can also be seen in the intestine (I). Expression 
is further increased by E14.5 where staining can be seen in the intestine (I), 
umbilical artery (UA), bronchi (Br) abdominal aorta (aA), cerebral and trunk 
vasculature (V) and on the surface of the apex of the heart (*). No staining was 
detected in the thoracic aorta (tA), liver or any other organ. The bottom two 
panels are serial sections through an E14.5 embryo that were stained for b-
galactosidase (blue stain) and hematoxylin and eosin (X-Gal/H&E) or smooth 
muscle myosin heavy chain (SM1, green), as described in ʻMethodsʼ. Scale bar 
represents 100µm. β-galacotsidase and SM1 staining can be seen in the midgut, 
umbilical artery (UA) and umbilical vein (UV). 
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Figure 8. Expression of an Hprt-targeted SM22α  transgene in adult mice. 
Tissues were rapidly dissected from a positive hemizygous male Hprt-targeted 
536bp SM22α promoter (-475 to +61) AUG-LAC transgenic mouse, fixed and 
 Spinal Cord 
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stained for β-galactosidase expression as described in ʻMethodsʼ. This transgene 
resulted in high levels of β-galactosidase expression in smooth muscle tissues of 
the mesenteric arteries (mA) and veins (mV), renal artery (RA) and vein (RV), 
abdominal aorta (aA), and vena cava (aV), thoracic aorta (tA) and vena cava (tV), 
pulmonary artery (PA) and vein (PV), bronchi (Br), atria (AT), coronary and brain 
vessels, bladder and gallbladder. No expression was detected in colon, 
duodenum, stomach, jejunum, uterus or in skeletal muscle cells. Identical 
patterns of transgene expression were observed in two hemizygous male and 2 
homozygous female mice obtained from each of two SM22α transgenic lines. 
Each of these lines was generated from an independently targeted ES cell clone. 
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Figure 9. Expression of Hprt-targeted SM22α  transgenes in embryonic 
mice. Timed embryos were obtained from Hprt-targeted 536bp SM22α promoter  
(-475 to +61) AUG-LAC transgenic mice as indicated. Positive male mice were 
identified by PCR using transgene specific primers and primers to the ZFY locus 
which is located on the Y chromosome. Embryos were processed for 
histochemical detection of β-galactosidase expression as described in ʻMethodsʼ. 
Blue staining representing β-galactosidase expression can be seen in umbilical 
artery (UA) and vein (UV), vitelline artery (VA) and vein (VV), abdominal aorta 
(aA), heart (H) and somites (S) at E12.5. By day 14.5 expression decreased in 
the heart, somites and abdominal aorta.  
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Figure 10. Expression of Hprt-targeted telokin 270bp (-94 to +180) 
transgenes. Tissues were collected from a positive hemizygous neonatal male 
Hprt-targeted 270bp telokin promoter (-94 to +180) AUG-LAC transgenic mouse 
or from an E14.5 transgenic mouse. Tissues and embryos were processed for 
histochemical detection of β-galactosidase expression as described in ʻMethodsʼ. 
Blue staining representing β-galactosidase expression adult mice can be seen at 
low levels in bladder, mesenteric vessels and brain vasculature. Blue staining in 
E14.5 is seen in umbilical artery (UA). An identical staining pattern was also 
observed in hemizygous male mice obtained from an independently targeted ES 
clone. 
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Table 1. Relative expression levels of β-galactosidase transgenes 
 
Transgene Expressing/ 
Total Lines 
Relative Expression Levels       
  Blad Gut Brai
n 
Uterus Aor. 
Arch 
Ab. 
Aorta 
E14 
Vasc 
E14 
Gut 
E14 
Ect 
T370  
(-190 to 
+180) 
AUG LAC 
4/14 Line 
 1 
 2 
 3 
 4 
 
++ 
+/- 
+ 
+++ 
 
++ 
+/- 
+ 
+++ 
 
- 
- 
- 
- 
 
+ 
+ 
+++ 
male 
 
- 
- 
- 
- 
 
+/- 
- 
+ 
+ 
 
- 
- 
nd1 
nd1 
 
- 
- 
nd1 
nd1 
 
+++ 
- 
nd1 
nd1 
T370  
(-190 to 
+180) 
pWhere 
3/6 Line 
 1 
 2 
 3 
 
+++ 
+++ 
+ 
 
+++ 
+++ 
+/- 
 
- 
- 
- 
 
+++ 
male 
male 
 
- 
- 
- 
 
+ 
- 
- 
 
-/+ 
nd1 
nd1 
 
++ 
nd1 
nd1 
 
- 
nd1 
nd1 
T370 
(-190 to 
+180) Hprt 
3/3 
Chimeras 
 1 
 2 
 3 
 
 
 
+++ 
+++ 
+++ 
 
 
+++ 
+++ 
+++ 
 
 
- 
- 
- 
 
 
- 
nd 
nd 
 
 
- 
- 
- 
 
 
+ 
+ 
+ 
 
 
+ 
+ 
nd 
 
 
++ 
++ 
nd 
 
 
- 
- 
nd 
 
Blad, Bladder; Aor.Arch, aortic arch; Ab.Aorta, abdominal aorta, E14 Vasc, E14 
vasculature, E14 Ect, E14 ectopic expression (none smooth muscle). 
nd, not determined 
nd1, no embryos analyzed, as founder produced no pups. 
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Table 2.  Hprt-targeted transgene expression pattern 
 
           Mice 
 
 
Tissue 
Endogenous 
Telokin 
T370 
(-190 to 
+180) 
T270 
(-90 to 
+180) 
T CArG mut. 
(-190 to 
+180) 
Endogenous 
SM22a 
SM22 
(-475 to +61) 
Bladder +++ +++ + - +++ +++ 
Colon +++ +++ - - +++ - 
Ileum +++ +++ - - +++ - 
Jejunum +++ +++ - - +++ - 
Duodenum +++ +++ - - +++ - 
Stomach +++ +++ - - +++ - 
Gallbladder + + - - N +++ 
Ureter ++ +++ - - N - 
Vas 
Deferens 
+++ - - - N - 
Bronchi +++ +++ - - +++ + 
Uterus +++ - N N +++ - 
Mesenteric 
vessels 
N ++ + - +++ +++ 
Renal 
vessels 
+ ++ + - N +++ 
Thoracic 
aorta 
- - - - +++ +++ 
Coronary 
vessels 
- - - - +++ +++ 
Brain 
vessels 
N ++ + - +++ +++ 
Skeletal 
muscle 
- - - - - (adult) - (adult) 
 
N, not analyzed 
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CHAPTER III 
 
TYPE 1 DIABETES LEADS TO ALTERED CALCIUM SIGNALING IN 
CHRONIC AND ACUTE DIABETIC MICE 
 
Introduction 
 
As many as 76% of diabetic patients at some point in the course of their disease 
develop gastrointestinal (GI) symptoms such as dysphagia, vomiting, 
constipation, diarrhea or fecal incontinence [74]. Constipation is the most 
common symptom and affects approximately 60% of patients [74, 75]. GI 
symptoms have been linked to poor glycemic control rather than duration of the 
disease [98]. Animal studies have shown that diabetes can lead to accelerated or 
delayed GI motility depending on the animal model used and the specific parts of 
the GI tract tested. Studies in an STZ-induced diabetic rat model revealed 
increased small intestine smooth muscle mass and increased colon contractility 
[91, 92]. The spontaneous contractile activity in STZ-induced diabetic rat colon 
smooth muscle was increased [138] without a change in intracellular Ca2+ 
handling [94] while in ileum intracellular Ca2+ handling was decreased [94]. 
Conversely in STZ-induced diabetic mice the colon smooth muscle contractile 
response to carbachol stimulation was weaker when compared to control animals 
at 4 and 8 weeks following STZ treatment [93]. In these mice this was also 
associated with delayed gastric emptying and increased intestinal transit time 
[86]. Diabetic db/db mice also show slower gastric emptying and prolonged whole 
gut transit time as compared to wild type mice [79]. These mouse models are 
consistent with human studies that demonstrated impaired colonic smooth 
muscle contractility in diabetic patients [139].  
 
Most studies attribute GI motility changes to autonomic or enteric nervous system  
(ENS) neuropathy [78-83, 139]. A study using non-obese diabetic (NOD), STZ-
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induced diabetic and db/db mice models demonstrated that NOD and STZ mice 
develop autonomic neuropathy while chronically diabetic db/db mice fail to 
develop neuritic dystrophy [78]. STZ-induced diabetic rats have been reported to 
show decreased number of enteric neurons in colon and stomach after only 7 
days of hyperglycemia [84, 85]. Human studies have also demonstrated a loss of 
enteric neurons in colons from diabetic patients [139]. However, few studies have 
explored the possibility that there are also defects in GI smooth muscle itself or 
shown how these defects progress during development of the diabetic state. In 
STZ-induced diabetic mice and db/db diabetic mice impaired stomach smooth 
muscle contractility has been reported to be due to alterations in muscarinic 
receptor coupling through GTP-binding proteins [95]. Similarly in diabetic BB/W 
rats a decreased contractile response of stomach smooth muscle resulted from 
altered intracellular signal transduction through IP3 and PKC pathways [96]. In 
some severe diabetic cases in both rat models and human patients where 
hyperglycemia is controlled poorly, gastroparesis occurs that is associated with 
gastric smooth muscle myopathy [96, 97]. Mechanistically, prolonged 
hyperglycemia can lead to increased O-glycosylation of proteins as a result of 
increased flux of glucose through the hexosamine pathway.  Increased global O-
glycosylation in cardiac and skeletal muscles has been shown to decrease Ca2+ 
sensitivity in these tissues and attenuate contractility [101, 102, 104]. Although 
the affects of O-glycosylation on colonic contractility have not been explored. 
Recently it has been shown that that reduction in insulin/IGF-I in diabetic mice 
causes decreased stem cell factor (SCF) production resulting in smooth muscle 
atrophy that eventually leads to ICC depletion [87]. These results suggest that 
myopathy may play a more central role in diabetic gastroenteropathies than 
previously recognized. They also suggest a role for insulin depletion in addition to 
hyperglycemia in progression of the smooth muscle dysfunction.  
 
The main goal of the current study was to determine the affects of diabetes on 
colon smooth muscle structure and function in a type 1 diabetic mouse model 
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induced by low dose STZ. Animals in this model develop hyperglycemia and 
hypoinsulinemia rapidly and maintain these changes for several weeks. We 
observed that STZ-induced diabetic mice have decreased colonic contractility 
and motility which develops rapidly within 1 week and is maintained for more than 
7 weeks. At early time points the decreased contractility is likely a result of 
impaired Ca2+ handling within the colonic smooth muscle cells that subsequently 
leads to more pronounced Ca2+ defects during prolonged exposure to 
hyperglycemia and hypoinsulinemia. 
 
 
Methods 
 
Streptozotocin (STZ)-induced diabetic mice. 9-12 week old C57BL6 mice 
were injected intraperitoneally with freshly prepared streptozotocin (STZ) (Sigma, 
S0130) at dose 55mg/kg for 5 consecutive days. Mice developed hyperglycemia 
(>200 mg/dl) within one week after injection and were sacked 1 week or 7-8 
weeks following the last injection of STZ. Blood glucose levels were measured 
using an Accu-Chek Aviva glucose measuring kit (Roche). All animal procedures 
were approved by the Indiana University School of Medicine IACUC committee. 
 
Computed Tomography. For in vivo GI motility measurements, mice were 
fasted over a 12-hour period then 100µL of the oral contrast agent Gastrografin 
(Bracco Diagnostic Inc) diluted with 300µL saline was given through oral gavage. 
CT images were subsequently acquired at 3, 5, 9 and 15 hours after 
administration of the contrast agent. For all scans, an x-ray voltage of 90kVp and 
an anode current of 100mAs were utilized. CT imaging was performed with a 
high-speed clinical CT scanner, a Siemens Somatom Sensation-16, capable of 
obtaining a mouse volumetric image within 1 minute.  The image voxel resolution 
was 300µ x 300µ x 625µ. A 3D volume rendering was generated using Siemensʼ 
image processing workstation equipped with the “Syngo” software. During 
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imaging, mice were kept anesthetized with 1.5% isoflurane (0.8L oxygen/minute). 
Between each scan mice were awake and received regular water and food. The 
GI motility was visualized by comparing images at different time points.  
  
Contractility measurements of colon rings. Colons were dissected and cut 
into 0.5cm long circular rings. 4 rings from the proximal and 4 from the distal part 
of the colon (Figure 12a) were placed in Krebs buffer in an organ bath (Kent 
Scientific) and attached to isometric force transducers. An optimal resting tension 
of 1.5g was determined empirically following stimulation with 60mM KCl. Colon 
rings from control and STZ-induced diabetic animals were equilibrated at optimal 
resting tension in Krebs buffer for 1h and contracted using 60mM KCl. After 
contraction rings were washed for 30min and the contraction repeated. Samples 
from each experiment were paired and data expressed as percentage of the KCl 
induced contraction. 
 
Ca2+ imaging. The ratio-metric imaging of Fura-2AM fluorescence was employed 
to monitor intracellular Ca2+ changes in colon strips. Ratio-metric imaging 
eliminates the artifacts associated with the tissue movement during KCl 
applications. 1mm wide colon strips were dissected free of epithelia and loaded 
with Fura-2AM for 5-14 hrs at room temperature in phosphate buffer solution 
containing 0.901mM Ca2+, 0.493mM Mg2+, 5.56mM glucose and 0.327mM 
pyruvate, 40µM Fura-2AM and 1% BSA. The Fura-2AM loaded colon strips were 
washed in standard external solution containing 145mM NaCl, 2.5mM KCl, 1mM 
CaCl2, 1mM MgCl2,10mM HEPES and 5.5mM glucose pH7.3 without Fura-2AM 
and were incubated for additional 1-3hrs at room temperature before the 
experiment, allowing complete Fura-2AM hydrolysis. Ca2+ imaging was 
performed using a monochromator-based TillPhotonics imaging system attached 
to an inverted Zeiss microscope equipped with a “Fluor” 2.5x objective and a 
back-illuminated Andor CCD camera. Fura-2AM was alternatively excited at 
345nm and 380nm. The emitted light was collected using a 510nm long-pass 
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filter. The TillVision software was used to control all fluorescence imaging 
experiments and to perform the analysis of images. Images were acquired every 
5seconds. The background fluorescence was subtracted. The intracellular Ca2+ 
concentration was calculated using the equation [Ca2+ ]i = Kd  x [(R-Rmin)/(Rmax-R)] 
x (Fmax(380)/Fmin(380)). The Kd value of 225nM was used. To determine the Rmax 
value, the strips were bathed in a solution containing 135 mM NMDG, 10 mM 
HEPES, 10mM CaCl2, 5.5mM Glucose, 10mM Ionomycin Ca2+ salt, pH7.3. The 
Rmin value was determined in a solution containing 145mM NaCl , 10mM EGTA, 
10mM HEPES, 5.5mM Glucose, 10mM EGTA, Ca2+-free Ionomycin, pH7.3. High 
KCl solution contained 145mM KCl, 1mM CaCl2, 1mM MgCl2,10mM HEPES, 
5.5mM Glucose, pH7.3. 
 
RNA analysis. Mouse colon was dissected and the epithelial layer was removed 
by mechanical scraping. RNA was extracted from distal colon as described 
previously [140]. 0.5µg of RNA was used as template for reverse transcription 
(RT). Gene expression levels were measured by quantitative real time PCR using 
SYBR green PCR master mix (Roche) and a 7500 Real Time PCR system 
(Applied Biosystems). 5µl of 1:5 diluted cDNA was used for each reaction. All 
PCR reactions were performed in duplicate. Primers used are shown in table 3.  
 
Western blot analysis. Protein from proximal or distal colon was extracted with 
RIPA lysis buffer. Protein concentrations were determined by using a BCA 
Protein Assay kit (Pierce). Proteins were fractionated on 5.0, 7.5 or 15% 
polyacrylamide gels and transferred to nitrocellulose or polyvinyl difluoride 
membranes. Membranes were then probed with a series of antibodies. 
Antibodies used for western blotting were against: MLCK (Sigma, clone K36, 
1:10,000), SM α-actin (Sigma, clone 3A1, 1:10,000), SM22α (rabbit polyclonal 
antibody directed against the peptide CGPDVGRPDRGRLGFQVW, Proteintech, 
1:10,000), telokin (1:6,000) [16], SM1, SM2, phospholamban [31], caldesmon 
(Sigma, clone C21, 1:10,000), GAPDH (Novus, clone 1D4, 1:5,000), PMCA4 
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ATPase (Thermo Scientific, cone JA9, 1:1,000), SERCA2 (Cell Signaling, 
1:1,000), IP3R2 (Santa Cruz, clone C-20, 1:1,000), Cav1.2 (Alomone, 1:200), 
Cav1.2 (Santa Cruz, clone H-280, 1:1,000), O-linked N-Acetylglucosamine 
(Thermo Scientific, clone RL2, 1:1,000). Primary antibodies were detected using 
horseradish peroxidase-conjugated secondary antibodies and visualized and 
quantitated using chemiluminescence on a G-Box imaging system (Syngene)  
 
Immunohistochemical staining. Tissues were collected from control and 
diabetic mice, and fixed in 4% paraformaldehyde solution for 24h and processed 
for paraffin embedding. After embedding 6µm sections were cut and stained with 
hematoxylin and eosin.  
 
In vitro O-glycosylation. To test the direct effects of protein O-glycosylation on 
smooth muscle contractility colonic smooth muscle rings were incubated with 
0.05mM glucosamine in Krebs buffer for 1h. 60mM KCl induced contractile 
responses were measured before and after glucosamine treatment. After 
contractility measurements, samples were processed for western blot analyses to 
confirm that the experimental protocol resulted in globally enhanced O-
glycosylation. 
 
MLC phosphorylation. Distal colon was isolated, cut in 0.5cm circular rings and 
hung in an organ bath as described above for contractility measurements. 
Tissues were flash frozen in the basal non-contracted state or at the peak of 
contraction initiated by 60mM KCl stimulation. Myosin light chain phosphorylation 
levels were measured by western blotting of proteins separated on urea/glycerol 
gels as described previously [141]. 
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Results 
 
STZ-induced diabetic mice have decreased overall gastrointestinal tract 
motility. Computed Tomography was used to assess the rate of food transit 
through the GI tract of control and diabetic animals 7 weeks following STZ 
injections. At the earliest time point analyzed (0 hour) contrast agent was found 
mainly in the stomach and was starting to enter the small intestine in both mouse 
groups (data not shown). Within 3 hours, although some contrast agent reached 
the rectum in both control and diabetic mice (Figure 11), there was more residual 
contrast left in the stomach and small intestine of the diabetic animals. After 5 
hours contrast agent was seen primarily in the colon and rectum of control mice 
while in diabetic mice, a significant amount of contrast was still visible throughout 
the whole of the small and large intestine. In control mice, the contrast agent was 
completely excreted between 9 and 15 hours post gavage. In contrast, in diabetic 
mice large amounts of contrast material still remained in the small and large 
intestine even 15 hours after gavage. These data demonstrate that the overall 
gastrointestinal transit time in diabetic animals was longer than in control mice. 
The CT scan data show that motility in diabetic animals is decreased in the 
stomach as well as small and large intestine resulting in an overall increased GI 
transit time. These results correlate with patient data showing significant 
constipation in large proportion of the diabetic human population [74, 75]. In 
addition, from both CT scans and also direct dissection of the GI tract the 
intestine appeared dilated in diabetic mice when compared to controls, possibly 
due to pseudo-obstruction in the lower GI tract. 
 
STZ-induced diabetic mice show decreased colon contractility. To better 
understand the mechanisms responsible for the decreased motility in diabetic 
mice we analyzed the contractility of colon rings ex vivo. To avoid neuronal 
pathway, we analyzed the ability of the rings to contract in response to direct 
depolarization induced by 60mM KCl. This approach bypasses the 
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neuromuscular synaptic transmission pathway and thus allows us to directly 
assess the contractility of the colonic smooth muscle itself. To determine if there 
were localized or global changes in colonic contractility the colon was divided into 
8 segments and the contractility of each segment measured separately (Figure 
12A). In diabetic mice, rings from the proximal part of the colon (P1 to P3) did not 
show any statistically significant changes in contractility when compared to 
control animals (Figure 12B, C). In contrast, the more central and distal P4 to D2 
parts of the colon showed 30-70% decreases in contractility in diabetic mice 
compared to control mice, with the most pronounced decrease (70%) found in 
the D4 part (Figure 12B, C). After combining data from all colonic segments the 
colons from diabetic mice showed a statistically significant decrease in overall 
colonic contractility as compared to control mice (Figure 12D). 
 
Long term diabetic mice have increased basal intracellular Ca2+ levels and 
decreased Ca2+ response to KCl stimulation. To begin to unravel the causes 
of the contractility defects, we examined changes in intracellular calcium in 
response to KCl stimulation. Strips of colonic smooth muscle were obtained from 
the central region of the colon and loaded with Fura-2 for ratio-metric calcium 
imaging. Ratio-metric measurements showed a large increase in the basal Ca2+ 
levels in strips obtained from long term diabetic mice as compared to control 
mice (Figure 13A, B). These levels calibrated to approximately 200nM Ca2+i in 
control mice and 600nM in diabetic mice (data not shown). In addition, the 
calcium transient generated in response to KCl stimulation was approximately 
60-70% lower in STZ-induced diabetic mice when compared to control mice 
(Figure 13A, C). Despite the elevated basal intracellular calcium levels seen in 
the diabetic mice there was no significant change in the basal myosin light chain 
phosphorylation levels in these mice (Figure 13D). 
 
Long term diabetic animals show significant changes in levels of calcium 
handling proteins. In order to determine the mechanisms that may lead to the 
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alteration in basal and KCl-stimulated Ca2+ levels we performed qRT-PCR and 
western blot analysis of a wide panel of proteins known to be important for 
regulating intracellular calcium levels (Figure 14). This analysis revealed an 
approximately two-fold increase in SERCA2b (sarcoplasmic reticulum calcium 
pump) and IP3R2 (IP3 receptor) mRNA levels in long term diabetic mice as 
compared to control mice (Figure 14A). Cav1.2b (L-type calcium channel), 
PMCA4 (plasma membrane calcium ATPase), RyR2 (ryanodine receptor 2)and 
NCX2 (sodium calcium exchanger) mRNA levels also showed a trend toward an 
increase in diabetic mice, however, due to the variability among animals these 
changes did not show statistical significance (Figure 14A). In contrast, SERCA2b 
and IP3R2 protein levels decreased 20-40% in diabetic mice  (Figure 14B). 
Cav1.2b protein levels were not changed in diabetic mice, while PMCA4 protein 
levels increased by 20% in diabetic mice (Figure 14B). In addition, we did not 
observe any significant changes in smooth muscle contractile (myosin, actin) or 
regulatory proteins (caldesmon, SM22α, telokin) at either the mRNA or protein 
levels (Figure 14A, D). 
 
Contractility in short term diabetic mice is decreased due to an attenuated 
intracellular Ca2+ response and decreased myosin light chain 
phosphorylation. The complex and somewhat confounding changes in 
expression of calcium handling proteins described above, suggest that after 7 
weeks of hyperglycemia adaptive changes may have occurred in the diabetic 
mice in an attempt to compensate for an initial defect. To try to identify which 
changes may represent the initial defect we analyzed diabetic mice that had been 
hyperglycemic for a much shorter time (less than 1 week). Mice that have been 
hyperglycemic for less than1 week (sacrificed 1 week after the last STZ injection) 
also showed a decreased contractile response to KCl in the middle portion of the 
colon (P4 and D4) (Figure 15A). Ratio-metric measurements of intracellular 
calcium showed no changes in the basal Ca2+ levels but a lower Ca2+ increase in 
response to KCl in these diabetic mice as compared to controls (Figure 15B, C). 
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Collectively, these data suggest that an initial defect in depolarization stimulated 
Ca2+ entry is later confounded by an elevation in basal intracellular Ca2+ which 
occurs following prolonged hyperglycemia. Despite the attenuated calcium 
response, we observed no significant changes in protein and mRNA levels of the 
L-type channel, SERCA 2 and IP3R2. A statistically significant but small 
decrease was detected in PMCA4 protein levels (Figure 15D, E, F).  Consistent 
with the intracellular calcium measurements there was no differences in the basal 
myosin light chain phosphorylation levels between diabetic and control mice 
(Figure 15G). However, KCl stimulated myosin light chain phosphorylation levels 
were lower in diabetic mice as compared to controls (Figure 15G). 
 
Long term hyperglycemic mice have increased global O-glycosylation 
levels although elevated O-glycosylation in vitro does not significantly 
affect contractility. Although we did not see any changes in expression of 
calcium channels or calcium handling proteins in mice which have been 
hyperglycemic for less than 1 week it is possible that the function of these 
molecules may be altered. One of the common ways in which hyperglycemia can 
modify proteins is through elevated O-glycoslyation [142]. Previous studies in 
cardiac and skeletal muscle have shown that STZ-induced diabetic mice have 
increased global O-glycosylation levels in these tissues that leads to decreased 
contractility [101, 102, 104]. Consistent with these findings western blot analysis 
of protein extracted from the middle part of the colon, showed increased O-
glycosylation levels in our STZ-induced diabetic mice (Figure 16A). To determine 
if increased O-glycosylation could lead to decreased colonic contractility we 
treated colon rings from control mice with glucosamine to increase O-
glycosylation levels directly and determined the subsequent affects on 
contractility. After 1h glucosamine treatment rings had elevated global O-
glycosylation levels comparable to those seen in STZ-induced diabetic mice 
(compare Figure 16A to 16B). Although contractility of glucosamine treated rings 
was slightly decreased this did not reach statistical significance (Figure 16C).   
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Long term diabetic mice show increased iNos mRNA levels in the colon 
smooth muscle layer, but no other signs of inflammation. To rule out the 
possibility that the attenuated contractility of the colons from diabetic mice is due 
to a thinner smooth muscle layer, we examined hematoxylin- and eosin-stained 
cross-sections. Smooth muscle layer thickness and nuclear density (data not 
shown) were not different between diabetic and control mice (Figure 17A). As 
inflammatory cytokines are known to attenuate GI smooth muscle contractility 
[117] and the STZ-diabetic model has been reported to exhibit elevated 
inflammation, we examined the possible contribution of elevated cytokines in the 
attenuated contractility observed in the colons from diabetic mice. 
Immunohistological analysis of macrophages in the colon revealed that there are 
no significant differences between control and STZ-induced mice. In addition, 
although qRT-PCR analysis revealed a 4-fold increase in iNos mRNA levels in 
colon smooth muscle tissues from diabetic mice 7 weeks after STZ treatment no 
changes were observed after 1 week (Figure 17B). In addition, in the long term 
diabetic animals there was a 50% decrease in IL1α levels and no significant 
changes in TNFα levels (Figure 17E). These data would suggest that there is not 
a marked inflammatory response in the colon at either 1 or 7 weeks following 
STZ injection as this would be expected to result in an elevation of several 
cytokines. However, an increase in NO produced by iNos could be contributing to 
the attenuated contractility in the long term diabetic mice.  
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Discussion 
 
Previous studies have demonstrated that diabetes affects GI motility through 
causing neuronal damage. For example, studies in STZ-induced diabetic rats 
showed a neuronal defect in the duodenum and colon following a short term 
hyperglycemic exposure of 7 days [85, 143]. However, few studies have explored 
possible effects of diabetes directly on colonic smooth muscle.  We observed that 
mice with long term hyperglycemia for 7-8 weeks exhibited a similar impairment 
in the whole gut transit time to that reported previously in mouse and human 
studies (Figure 11) [79, 144, 145]. These findings are consistent with constipation 
being the most common GI disorder observed in human diabetic patients. 
Results from our ex vivo contractility measurements further demonstrate that in 
this type 1 diabetic mouse model both short term (less than 1 week) and long 
term (7-8 weeks) hyperglycemia results in a direct impairment of colonic smooth 
muscle contractility, independent of any potential neuronal effects (Figures 12 
and 15). This impaired contractility is not associated with a general 
dedifferentiation of colonic smooth muscle as expression levels of smooth muscle 
contractile proteins were not altered in any of these diabetic mice (Figure 14A, 
D). The attenuated contractility is also not a result of grossly altered smooth 
muscle structure as histology sections of the middle part of the colon showed no 
significant structural changes in the smooth muscle of the colon of STZ-induced 
diabetic mice (Figure 17A). Perhaps surprisingly, we observed regional 
differences in the contractile response along the length of the colon. The 
decreased contractile response to KCl was most pronounced in the middle 
portion of the colon (P4-D2 in Figure 12). There are a number of possible 
explanations for this regional variation. For example, the anatomical structure of 
the colon could be contributing to this phenomena. In the mouse, the middle 
portion of the colon exhibits a sharp bend as it is positioned in the abdominal 
cavity. This region also exhibits a steep decrease in its diameter when compared 
to the more proximal part. It is likely that these combined anatomical features 
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provide increased resistance to the movement of fecal matter through this region. 
Alternatively the distinct neural innervation of the proximal (vagal) and distal 
(pelvic) portions of the colon could be contributing to the regional pathological 
changes [147, 148] and causing a secondary functional atrophy. 
 
Our observations that the impaired colonic contractility in diabetic mice is 
associated with an impairment in the depolarization-induced intracellular calcium 
increase is consistent with previous studies in diabetic rats which also exhibited 
impaired calcium handling [94, 138]. Moreover, our temporal data suggest that a 
primary defect in depolarization-induced calcium increases, eventually lead to an 
elevation in basal intracellular calcium levels following more long term exposure 
to hyperglycemia (Figures 13 and 15B). By inducing contraction of colonic rings 
with direct KCl-induced depolarization instead of a natural neurotransmitter ligand 
such as acetylcholine, or electrical field stimulation of the nerves, we were able to 
bypass the neuronal pathways and directly assess the function of the colonic 
smooth muscle. Contractions induced by KCl depolarization occur primarily 
through voltage dependent opening of L-type Ca2+ channels in the sarcolemma 
and perhaps to a small extent to release of calcium from intracellular stores [146]. 
The attenuated contractility observed following either 1 week or 7 weeks of 
hyperglycemia, suggests a direct defect in depolarization-dependent contractility 
of colonic smooth muscle that likely involves defects in the L-type Ca2+ channels 
(Figures 18, 19). In support of this, short-term diabetic mice exhibited a 
statistically significant but small decrease in PMCA4 protein levels, but no 
significant changes in the expression of any other of the L-type Ca2+ channel or 
any other calcium handling proteins (Figures 15, 18). Although statistically 
significant, the decrease in PMCA4 may not be sufficient to account for the 
attenuated Ca response. Other possibilities include posttranslational 
modifications to calcium regulatory proteins. In support of this, previous studies 
have shown that diabetes can lead to oxidative stress in smooth muscle [149-
151] and oxidative stress in cardiac myocytes has been shown to cause nitration 
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of L-type channels leading to their decreased activity [112, 152]. Whether this 
occurred in response to STZ-induced hyperglycemia or not will be examined in 
future studies. 
 
In contrast to short-term diabetic mice, long-term hyperglycemic mice (7-8 
weeks) exhibited an elevated basal calcium level in addition to the attenuated 
KCl-induced calcium increase (Figures 13B, 19). These changes were 
associated with changes in several calcium handling mRNA and proteins levels. 
mRNA levels of SERCA2b and IP3R2 were significantly up-regulated and mRNA 
encoding Cav1.2b,  PMCA4, RyR2 and NCX2  trended toward being elevated 
(Figures 14, 19). In contrast, western blotting revealed a down-regulation of 
IP3R2 and SERCA2 proteins (Figures 14, 19). These inconsistencies between 
mRNA and protein levels could be explained by compensatory transcriptional 
mechanisms occurring in response to downregulated protein levels due to protein 
posttranslational modifications. This would be consistent with previous studies 
have shown that diabetes induced oxidative stress can lead to nitration of 
SERCA [153]. Nitration in turn can attenuate SERCA activity and lead to its 
degradation resulting in impaired Ca2+ uptake into the SR. This could be 
contributing to the elevated basal calcium levels observed in colon smooth 
muscle following long term diabetes. Although we observed an increase in basal 
Ca2+ levels in colon from long term diabetic mice these changes did not lead to 
increased basal MLC phosphorylation (Figures 13D, 19). This result would 
suggest that the myosin light chain phosphorylation pathway has been 
desensitized to the calcium signal possibly through activation of the MLC 
phosphatase or inhibition of the MLC kinase in these mice. 
 
Studies have shown that inflammatory cytokines such as TNFα [117] can also 
lead to decreased smooth muscle contractility in the gut but the influence of 
cytokines in altering GI motility in diabetes has not been examined. In our studies 
we did not find any evidence of macrophage activation in the colon of diabetic 
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mice nor could we detect any elevation of TNFα mRNA, and in fact observed a 
decrease in IL1a mRNA levels (Figure 17B). We did however, detect higher 
levels of iNos mRNA in the smooth muscle of long term but not short term 
diabetic mice (Figure 17B, C). Together these data suggest that the increased 
iNos expression likely results from long-term oxidative stress rather than from an 
intestinal inflammatory response.  
 
The diabetic state can lead to several different post-translational modifications of 
proteins, including nitration and O-glycosylation [142, 154]. Hyperglycemia, in 
particular leads to increased O-glycosylation of proteins via increased flux 
through the hexosamine pathway. Consistent with studies in skeletal and cardiac 
muscles, we detected increased global O-glycosylation levels in colon smooth 
muscle from STZ-induced diabetic mice. Although O-glycosylation levels were 
increased in STZ-induced diabetic mice, in vitro studies in which colon rings were 
treated with N-acetylglucosamine for 1 hour to directly increase levels of O-
glycosylation did not show a significant decrease in their contractile response. As 
we still observed a global increase in O-glycosylated proteins, these findings 
suggest that increased O-glycosylation levels may not be the main contributor to 
the decreased contractility observed in STZ-induced diabetic animals.   
 
In summary, our results show that STZ-induced diabetic mice develop decreased 
colon contractility as early as 7 days after developing hyperglycemia. This 
decreased contractility is likely caused by an attenuated depolarization-induced 
calcium increase which leads to decreased myosin light chain phosphorylation 
and impaired contractility. The primary molecular defect that results in the 
attenuated calcium increase is most likely an alteration in the activity of L-type 
Ca2+ channels through posttranslational modifications such as nitration or O-
glycosylation. In long-term diabetes, we also observed increased basal 
intracellular Ca2+ levels that could be due to a decrease in SERCA2b level 
leading to decreased Ca2+ uptake to the SR. Together these data demonstrate 
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that in addition to any affects it may have on enteric neural innervation diabetes 
also has a direct effect on colonic smooth muscle cells that impairs their 
contractility. 
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Figure 11. CT scan reveals decreased GI motility in chronic diabetic mice. 
At 7-8 weeks after becoming hyperglycemic mice (n=3) were subjected to CT 
scan and compared to the control littermates injected with saline (n=2). CT 
images were taken 3, 5, 9, and 15 hours after contrast agent administration. In 
control mice throughout the scan contrast agent movement was faster and 
completely excreted after 9-15 hours, while contrast agent still detectable in 
diabetic mice at 15 hours. ST-stomach, SI-small intestine, LI-large intestine.
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Figure 12. Chronic diabetic mice show decreased colon contractility. At 7-8 
weeks after becoming hyperglycemic, mice colons were dissected for contractility 
measurements. (A) Colons were cut into 0.5 cm circular rings starting from the 
distal part, where D1 is assigned as the most distal part and P0 is the most 
proximal part. The proximal (P1-P4) rings and the distal distal (D1-D4) 4 rings of 
the colon were used for contractility measurements. (B) Representative tracings 
of colon ring contractility measurements after 60mM KCl stimulation. (C) 
Quantification of changes in contractility in control and STZ-induced mice of the 
different parts of the colon P1 (n=10), P2 (n=11), P3 (n=10), P4 (n=12), D4 (n=6), 
D3 (n=9), D2 (n=11), D1 (n=10). Changes in contractility of control mice are set 
to 100%. Each column represents the mean of different mice. Error bars 
represent standard deviation (±SD). (*P<0.05, **P<0.005, Student t-test). (D) 
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Quantification of the average contractility changes from all colonic rings (proximal 
and distal) (n=79). Changes in contractility of control mice are set to 100%. 
(***P<0.0005, Student t-test).  
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Figure 13. Basal intracellular Ca2+ levels are increased while the Ca2+ 
response to 60mM KCl is decreased in the middle part of the colon in 
chronic diabetic mice. (A) Representative averaged recordings of intracellular 
Ca2+ measured using Fura-2AM over the time. (B) Basal levels of intracellular 
Ca2+. (C) Changes in intracellular Ca2+ in response to 60mM KCl in control and 
STZ-induced diabetic mice. For (A-C) Each tracing/column represents the mean 
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of different mice (n=6-8). Error bars represent standard deviation (±SD). For (B) 
and (C) intracellular Ca2+ levels of control mice are set to 1. (*P<0.05, Student t-
test). (D) Myosin light chain phosphorylation was measured in the middle to distal 
part of colon (mechanically dissected free of the epithelial mucosa layer) by urea 
gel electrophoresis coupled to western blotting. MLC phosphorylation was 
expressed as MLCphosphorylated/MLCtotal. Each column represents the mean of 
samples obtained from 4 different mice. Error bars represent standard deviation 
(±SD). (*P<0.05, Student t-test).  
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Figure 14. Changes in mRNA levels and protein of calcium handling 
proteins in chronic diabetic mice. The middle to distal portion of the colon was 
dissected and cleaned free from the mucosal  layer. (A) RNA was isolated using 
Trizol (Invitrogen) and transcripts were quantitated by real-time RT-PCR. 
Transcript levels were firstly normalized to HPRT internal loading control and 
then samples from STZ-induced diabetic mouse colons normalized to those 
obtained from the control group of mice. Relative expression = 2-ΔΔCt, where ΔΔCt 
= (CtSTZ − CtHPRT) − (Ctcontrol − CtHPRT). Changes in mRNA levels of control mice 
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are set to 1. Each column represents the mean data obtained from several 
different mice (n=4-10). Error bars represent standard deviation (±SD). (*P<0.05, 
Student t-test). (B) Immunoblots of proteins extracted from the colons of control 
and STZ-induced diabetic mice. (C) Quantification of protein expression following 
normalizing to vinculin levels as a loading control.  Protein levels of control mice 
are set to 1. Each column represents the mean data obtained from 4 different 
mice. Error bars represent standard deviation (±SD). (*P<0.05, **P<0.005, 
Student t-test). (D) Smooth muscle contractile proteins are not changed in 
chronic diabetic mice. Immunoblots of proteins extracted from the middle part of 
the colon from chronic diabetic and control mice were performed as described in 
ʻCʼ. 
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Figure 15. Contractility in short term diabetic mice is decreased due to 
altered intracellular Ca2+ signaling. 1 week after becoming hyperglycemic mice 
colons were dissected for contractility measurements, Ca2+ imaging, mRNA and 
protein analysis. (A) Quantification of changes in contractility of rings obtained 
from the middle part of the colon (P4 and D4) combined (n=12). Changes in 
contractility following KCl stimulation are indicated in grams. (*P<0.05, Student t-
test). (B) Basal levels of intracellular Ca2+ in the smooth muscle of the middle 
portion of the colon. (C) Changes in intracellular Ca2+ in response to 60mM KCl 
stimulation of smooth muscle obtained from the middle portion of the colon from 
control and STZ-induced diabetic mice. Each column in (B) and (C) represents 
the mean data obtained from  several different mice (n=5-6). Error bars represent 
standard deviation (±SD). Intracellular Ca2+ levels of control mice are set to 1. 
(*P<0.05, Student t-test). (D) RNA from the middle to distal part of colon was 
isolated using Trizol (Invitrogen) and transcripts were quantitated by real-time 
RT-PCR. Transcript levels were firstly normalized to Hprt internal loading control 
and then samples from STZ-treated mice are expressed relative to those from 
control mice. Relative expression = 2-ΔΔCt, where ΔΔCt = (CtSTZ − CtHPRT) − 
(Ctcontrol − CtHPRT). Each column represents the mean of data obtained from 
several different mice (n=4-5). Error bars represent standard deviation (±SD). 
(*P<0.05, Student t-test). (E) Immunoblots of proteins extracted from the middle 
part of the colon of the mice described in panel (C). (F) Quantification of protein 
expression following normalization to vinculin as an internal control. Protein 
levels of control mice are set to 1. Each column represents the mean of samples 
obtained from 8 different mice. Error bars represent standard deviation (±SD). 
(*P<0.05, Student t-test). (G) MLC phosphorylation was measured in colonic 
muscles rings obtained form short term diabetic and control mice using urea 
PAGE and western blotting. Levels of MLC phosphorylation were measured in 
resting rings (basal MLC phosphorylation) and at the peak of a contraction 
initiated by 60mM KCl. MLC phopshorylation is expressed as 
MLCphosphorylated/MLCtotal. Each column represents the mean of data obtained from 
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7-8 different mice. Error bars represent standard deviation (±SD). (*P<0.05, 
Student t-test).  
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Figure 16. Chronic hyperglycemic mice have increased global O-
glycosylation levels while elevated O-glycosylation in vitro does not 
significantly affect contractility. (A) Immunoblots of proteins extracted from the 
middle part of the colon of long-term (7 week) diabetic and control mice. (B) The 
P4 portion of the colon from 12 week old control mice were dissected and hung in 
organ baths. Samples were treated with glucosamine for 1 hour and collected 
before contraction (-C), immediately after inducing contraction with KCl (+C) or 
after contraction followed by a 1 hour washout. Samples then were processed for 
western blot analysis using the RL2 antibody to detect O-glycosylated proteins. 
Immunoblots show increased global O-glycosylation levels after glucosamine 
treatment. (C) Contractility measurements of samples treated as described in ʻBʼ. 
Changes in contractility following glucosamine treatment are normalized to the 
changes in contractility before treatment (n=4-8). Error bars represent standard 
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deviation (±SD). -GlcNAc - no glucosamine treatment,  +GlcNAc - glucosamine 
treatment for 1hour. 
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Figure 17. Chronic diabetic mice show increased iNos mRNA levels in the 
colon smooth muscle layer. RNA was isolated from the colon of chronic 
diabetic and control mice by using Trizol (Invitrogen) and transcripts were 
quantitated by real-time RT-PCR. Transcript levels were firstly normalized to Hprt 
internal loading control and then samples from STZ-induced diabetic mouse 
colons normalized to those obtained from control mice. Relative expression = 2-
ΔΔCt, where ΔΔCt = (CtSTZ − CtHPRT) − (Ctcontrol − CtHPRT). Changes in mRNA levels 
of control mice are set to 1. Each column represents the mean of different mice 
(n=5-7). Error bars represent standard deviation (±SD). (*P<0.05, **P<0.005, 
Student t-test). 
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Figure 18. Defects occurring at acute state in STZ-induced diabetic mice. In 
acute diabetic mice L-type voltage gated channel mRNA and protein levels were 
not changed. KCl-induced stimulation led to decreased calcium influx suggesting 
functional defect of the L-type channel. No other transcriptional changes of 
calcium channels and receptors were observed, while PMCA4 protein levels 
were significantly decreased and SERCA2 protein showed trend to decrease. 
Decreased calcium influx leads to decreased myosin light chain phosphorylation 
and decreased contractility. 
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Figure 19. Defects occurring at chronic state in STZ-induced diabetic mice. 
In chronic diabetic mice, similar to acute diabetics, L-type voltage gated channel 
mRNA and protein levels were not changed. KCl-induced stimulation led 
decreased calcium influx while high basal intracellular calcium levels. SERCA2b 
mRNA levels were increased while protein levels were decreased. Similarly IP3R 
mRNA levels were increased while protein levels decreased. PMCA4 mRNA and 
protein levels were decreased. These results suggest that decreased contractility 
is due to elevated intracellular calcium levels and altered calcium influx and 
efflux/upteke to SR. These defects also lead to decreased myosin light chain 
phosphorylation in response to KCl. 
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Table 3. Primers used for qRT-PCR. 
 
Primers Forward Reverse 
Cav1.2b GCTACCTGGACTGGATCACC TTCCCTTTCTTCTGATCATGC 
PMCA1 TTAGTCTGGGAAGCATTACAAGATGTC
AC 
CTTCTTCCCCAACAGAAACTTCTCC 
PMCA4 ACGTCTTCCCACCCAAGGTTC CCAGCAGCCCACACTCTGTC 
TRPC1 TTCCAAAGAGCAGAAGGACTG CAAAGCAGGTGCCAATGAA 
TRPC4 GATGATATTACCGTGGGTCCTG GATTCCACCAGTCATGGATGT 
TRPC6 GCAGCTGTTCAGGATGAAAAC TTCAGCCCATATCATGCCTA 
Serca2b TCGACCAGTCAATTCTTACAGG CAGGGACAGGGTCAGTATGC 
RyR2 TTCAACACGCTCACGGAGTA TGCCAGGCTCTGCTGATT 
RyR3 CTGGCCATCATTCAAGGTCT GTCTCCATGTCTTCCCGTA 
IP3R1 GCACCGGAAGCTGAGAACT AATTTGTCGGAGTGCCTCAC 
IP3R2 GGCTCAGGCAGAAACAATG CTTCATCATCAAGCTGAACTGG 
IP3R3 TGCAGATCCCTTACGACAAGA ACTGGTGTGTGTAGCGCAGT 
NCX2 AAGCAGAAGCACCCGGATA TGCATAGTACTTGGCGATGC 
SM22 CGAAGCCAGTGAAGGTGCCTGAGAAC CCCAAAGCCATTAGAGTCCTCTGCA
CTGC 
Telokin GACACCGCCTGAGTCCAACCTCCG GGCTTTTTCCTCAGCAACAGCCTCC 
HPRT TGGCCCTCTGTGTGCTCAA TGATCATTACAGTAGCTCTTCAGTC
TGA 
iNos GGGCTGTCACGGAGATCA CCATGATGGTCACATTCTGC 
PAR2 GGACCGAGAACCTTGCAC GGAACCCCTTTCCCAGTG 
IL1a TGTAATGAAAGACGGCACACC TCTTCTTTGGGTATTGCTTGG 
TNFa TGCCTATGTCTCAGCCTCTTC GAGGCCATTTGGGAACTTCT 
Erg1 GCCGAGCGAACAACCCTAT CCATCGCCTTCTCATTATTCAGA 
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CHAPTER IV 
 
CONCLUSIONS AND FUTURE STUDIES 
 
Results from my thesis work have demonstrated that Hprt locus targeted single 
copy transgenes show reproducible appropriate levels and patterns of expression 
among different founder lines. Telokin promoter-driven transgene expression 
recapitulated the expression of endogenous telokin in adult and embryonic 
tissues. Thus, I was able to use the Hprt-targeted transgenic approach to further 
analyze regulatory elements within the telokin promoter. Although previous 
studies have shown that SM22α promoter-driven transgenes are restricted to 
arterial smooth muscle we observed high levels of transgene expression in 
bladder, gallbladder and veins when these transgenes were targeted to the Hprt 
locus (Figure 8). Thus, Hprt-targeted SM22α transgenes more closely 
recapitulate endogenous SM22α expression, which is expressed in all smooth 
muscle tissues [35, 129, 134]. The lack of transgene expression in GI and 
reproductive tract smooth muscle cells suggests that additional regulatory 
elements are required to drive SM22α expression in these tissues. Moreover, the 
expression of Hprt-targeted SM22α transgenes but not randomly integrated 
SM22α transgenes in bladder, gallbladder and venous smooth muscle cells 
suggests that chromatin remodeling complexes may be important for regulating 
SM22α expression in different smooth muscle tissues. My additional analysis of 
the telokin promoter showed that a promoter fragment extending from -90 to 
+180 had a marked decrease in expression when compared to a -190 to +180 
promoter (Figure 10). Transgene expression in the GI tract was particularly 
affected with only a few isolated cells staining positive for β-galactosidase activity 
(Figure 10). These data suggest that the -190 to -90 region of the telokin 
promoter is required for high levels of telokin expression particularly in smooth 
muscle cells of the GI tract. An Hprt-targeted telokin promoter-driven transgene 
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with a mutated CArG box exhibited no detectable β-galacosidase activity 
demonstrating that the CArG box is required for telokin expression in all smooth 
muscle tissues in vivo (Table 2). However, the -90 to +180 telokin promoter that 
contains the CArG box was not sufficient for expressing a transgene at significant 
levels in the GI tract, reproductive tract or in airway smooth muscle. These 
findings suggest the CArG box and adjacent AT-rich region are not sufficient for 
telokin promoter activity in vivo and that SRF and myocardin which interact with 
this region must cooperate with other factors to drive telokin expression in these 
tissues. Further studies are needed to determine which transcription factors are 
required for telokin expression in GI tract. Analysis of the sequence of the -190 to 
-90 region using rVISTA revealed the presence of conserved putative Sox and 
SMAD binding sites (Figure 20). SMAD family members have been shown to play 
a role in GI tract development hence it is tempting to propose that they may be 
contributing to telokin expression in the GI tract [9, 11, 12]. Sox family members 
have been shown to play a role in development of GI tract epithelium but their 
role in GI smooth muscle differentiation is unknown [135, 157]. My preliminary 
experiments using siRNA mediated silencing of Sox genes in primary cultures of 
GI smooth muscle cells suggest that Sox 4, 5, 6, 7 and 12 are possible 
candidates involved in telokin transcriptional regulation (data not shown). As 
knockdown of Sox genes could be indirectly affecting telokin expression it will be 
important to show that Sox proteins directly affect telokin transcription. To do this 
it will be necessary to verify the importance of the Sox binding site within the 
telokin promoter for directing expression in GI smooth muscle cells. Further 
studies using Hprt-targeted transgenes with the Sox binding site either deleted or 
mutated are being performed in order to achieve this goal. From in vitro 
experiments I also determined that SMAD signaling might play a role in 
regulating telokin expression in vitro, however it is unclear which family members 
are involved. BMP family members are expressed in mesenchyme and epithelial 
cells in the developing gut. In the GI tract, the TGFβ family member BMP4 plays 
a significant role during smooth muscle development [9, 10]. BMP4 plays 
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important roles in regulating both smooth muscle and epithelial proliferation and 
differentiation [11]. BMP2 can also enhance smooth muscle differentiation in vitro 
from embryonic stem cells to form contracting gut-like structures that express SM 
α-actin [12]. To identify whether TGFβ family members are important for telokin 
transcriptional regulation, we are planning to mutate the SMAD binding sites on 
the telokin promoter and determine whether these mutations lead to decreased 
promoter activity in the GI tract. If we observe decreased transgene activity, we 
would use a siRNA-mediated silencing approach together with luciferase assays 
to determine which TGFβ and SMAD family members are involved in regulating 
telokin transcription. These experiments will be coupled to ChIP assays to 
demonstrate direct binding of Sox or SMAD proteins to the telokin promoter. 
 
In parallel to my study investigating transcriptional regulation of telokin in GI 
smooth muscle I was interested in determining if this regulation may be altered in 
the diabetic state. Previous reports have shown altered colon smooth muscle 
contractility in diabetic patients and animal models. A study in diabetic rats 
implied that altered contractility possibly occurs through altered sensitivity to 
calcium in smooth muscle [94]. As telokin is known to play a role in smooth 
muscle calcium desensitization, my goal was to determine whether telokin 
expression is altered in colon smooth muscle of diabetic mice. In a type 1 
diabetic mouse model in which STZ was used to destroy the pancreatic beta 
cells, I found that telokin mRNA and protein levels were not changed. However, 
from an in vivo study of GI motility in these mice I found that long term 
hyperglycemia for 7-8 weeks resulted in a delayed whole gut transit time (Figures 
11, 19). Results from our ex vivo contractility measurements further demonstrate 
that in my type 1 diabetic mouse model, both short term (less than 1 week) and 
long term (7-8 weeks) hyperglycemia resulted in a direct impairment of colonic 
smooth muscle contractility (Figures 12, 15, 18, 19). As this was not due to 
changes in telokin expression I was interested in determining the mechanisms 
resulting in this smooth muscle contractility defect. Colonic rings were stimulated 
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with KCl to bypass neuronal pathways and directly assess the function of the 
colonic smooth muscle. The decreased contractile response to KCl was most 
pronounced in the middle portion of the colon (P4-D2 in Figure 12). These 
regional pathological changes could possibly be explained by the anatomical 
structure of the colon or distinct neural innervation of the proximal (vagal) and 
distal (pelvic) portions of the colon [147, 148]. Further studies showed that the 
impaired colonic contractility in diabetic mice is associated with an attenuation of 
the depolarization induced intracellular calcium increase that eventually leads to 
an elevation in basal intracellular calcium levels after 7 weeks of hyperglycemia 
(Figures 13c, 19). I also examined the expression of the proteins that are 
involved in regulation of intracellular calcium levels. In short term diabetic mice I 
observed statistically significant changes in protein levels of PMCA4 while no 
changes in the expression of any other proteins (Figure 15). These findings 
suggest that posttranslational changes, most likely of the L-type calcium channel 
are likely causing the attenuated calcium response following short term 
hyperglycemia (Figure 18).  
 
In our studies I did not find any evidence of inflammation related macrophage 
activation or elevation of TNFα in colons from diabetic mice while I did detect 
higher levels of iNos mRNA in the smooth muscle of long term but not short term 
diabetic mice (Figure 17). Together these data suggest that the increased iNos 
expression likely results from long term oxidative stress rather than from an 
intestinal inflammatory response and is thus unlikely to be contributing to the 
attenuated contractility seen after short term hyperglycemia. I also examined 
whether hyperglycemia leads to global O-glycosylation and evaluated itʼs 
possible role in mediating altered contractility.  I determined that O-glycosylation 
levels were increased in STZ-induced diabetic mice. However, my in vitro studies 
in which colon rings were treated with N-acetylglucosamine for 1 hour to directly 
increase levels of O-glycosylation, did not show a significant decrease in their 
contractile response. These finding suggest that increased O-glycosylation levels 
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may not be the main contributor to the decreased contractility observed in STZ-
induced diabetic animals. Alternatively it is possible that the O-glycosylation 
pathway may need to be activated for a prolonged period in order to effect 
contractility and my 1 hour incubation may not have been sufficient to achieve 
this affect. 
 
Overall my data demonstrate that type 1 diabetes leads to a direct defect in GI 
smooth muscle, however there are many questions that still should be answered 
before we will be in a position to design and appropriate treatment regime to 
alleviate these GI symptoms in patients. Diabetes is a multifactorial disease that 
affects different areas of the GI tract through distinct pathways. I think it would be 
useful to determine if in my STZ-induced diabetic mice the smooth muscle in 
other parts of GI tract (small intestine and stomach) have similar defects to those 
I observed in colon. The most likely explanation for the contractile defect that I 
observed in the colon of diabetic mice is an altered activity of the L-type channel. 
In future experiments it would be important to test this hypothesis directly. To do 
this we would use patch-clamp measurements of single colon smooth muscle 
cell. By using patch-clamp measurements we would be able to determine resting 
membrane potential as well as changes in the action potential in STZ-induced 
mice colons in response to KCl. As Ca2+ influx through the L-type calcium 
channels accounts for the upstroke of the action potentials in GI smooth muscle 
cells these electrophysiologycal measurements would enable us to directly 
measure L-type calcium channel activity. 
 
Results of my study suggest that post-translational modification of L-type 
channels, that alter channel activity, rather that changes in protein or mRNA 
levels could account for changes in calcium responses within colonic smooth 
muscle cells. Previous studies have shown that diabetes can lead to oxidative 
stress in smooth muscle [149-151] and studies with cardiac myocytes have 
shown that oxidative stress related nitration of L-type channels leads to their 
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decreased activity [112, 152]. Nitration in turn can attenuate SERCA activity and 
lead to itʼs degradation resulting in impaired Ca2+ uptake into the SR. Further 
studies should be done to determine whether nitration of the L-type channel is 
the main cause for defective calcium signaling in colonic smooth muscle cells. I 
also observed that at the later stages of diabetes mice had increased levels of 
iNos in the colonic smooth muscle layer without an increase in other 
inflammatory markers. These findings suggest that increased NO produced by 
iNos could be contributing to free radical damage and protein nitration and/or it 
could be directly inhibiting smooth muscle contractility. Thus, further studies to 
determine what role oxidative stress plays in increasing iNos production and 
whether the increased NO contributes to decreased motility either directly or 
indirectly through posttranslational modification of proteins should be determined.  
 
The colon is a complex organ consisting of a mucosal and submucosal layer, 
smooth muscle and neurons. To treat diabetes-related complications it would be 
beneficial to understand how each of these different tissues contribute to motility 
problems observed in the diabetic state. Many studies have shown diabetes-
related motility problems can be caused by neuronal damage. Recent studies 
have also shown that epithelial cells and microflora residing in the GI tract also 
can be affected in the diabetic state and in IBD alterations in gut microflora have 
been shown to lead to altered motility [158, 159]. However, interaction among 
different cell types in the diabetic state is not well studied. It have been shown 
that long term hyperglycemia leads to morphological changes in the autonomic 
nervous system and atrophy of ENS in the stomach and colon leading to motility 
problems [84, 85, 160]. Moreover, loss of myenteric neurons in STZ-induced 
diabetic rats has been detected as early as 7 days after the onset of diabetes 
[85].  In my study I observed decreased motility and altered calcium signaling 
within colonic smooth muscle itself as early as 1 week after hyperglycemia. Thus, 
it is still unclear whether neuronal damage occurs first leading to defects in 
smooth muscle or if these defects occur simultaneously and independently. 
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Never the less my data suggest that direct affects of diabetes on GI smooth 
muscle play a more significant role than was previously thought in causing 
intestinal dysmotility. Determining if the neuronal and muscle defects occur 
independently during the progression of diabetes will be important for developing 
more effective treatment rationales for the prevention of GI symptoms in diabetic 
patients. 
 
Another point of interest would be identifying the main players within the diabetic 
milieu that cause to GI dysmotility. Studies have shown that short-term 
hyperglycemia has reversible effects on gut motility in diabetic patients. These 
studies showed that a rise in blood glucose levels in type 1 diabetic patients for 
two hours slows down gastric emptying [155, 156].  Studies suggest that 
uncontrolled hyperglycemia leads to complications of diabetes by causing 
oxidative stress and neuronal damage in GI tract. One study shows that blood 
glucose levels rather than the length of diabetes is the main cause for GI 
dysmotility problems [98]. On the other hand insulin and IGF-1 receptors have 
been found in stomach smooth muscle and data indicates that they can increase 
SCF levels which prevents smooth muscle atrophy [87]. These results suggest 
that insulin depletion could contribute to impaired GI motility by promoting smooth 
muscle atrophy. It is still unclear whether similar defects occur in the small and 
large intestine. Also, it is unclear what role hyperglycemia and hypoinsulinemia 
have on smooth muscle pathophysiology in diabetic colonic smooth muscle.  
 
My study on colon smooth muscle investigated the effects of type 1-like diabetes 
characterized by hyperglycemia and hypoinsulinemia. However, GI problems 
occur also in patients with type 2 diabetes in which GI tract motility is also 
affected and patients suffer from similar symptoms as in type 1 diabetes. In 
further studies it would be beneficial to determine if similar smooth muscle 
defects with altered calcium signaling also occur in type 2 diabetic models such 
as seen in db/db and ob/ob mice. In these mouse models an insulin resistance 
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develops that leads to hyperglycemia and at least for a period of time 
hyperinsulinemia. These models may thus be useful in teasing out the relative 
roles of hyperglycemia and hypoinsulinemia in impairing GI contractility. These 
mouse models, however, also develop dyslipidemia and obesity which 
themselves could affect GI motility. The different mouse models also have 
different degrees of neuronal damage, thus comparing these mice models would 
be helpful in determining whether neuronal damage leads to smooth muscle 
defects or if these defects occur simultaneously [78, 161].     
 
Overall, my current study shows that Hprt-targeted transgenic mice exhibit a 
reproducible pattern and level of transgene expression. This approach is thus a 
useful model for promoter analysis within GI tract smooth muscle. I also 
determined that the CArG element in the telokin promoter is necessary for telokin 
expression in all smooth muscle cells while an adjacent region is necessary for 
telokin expression specifically in the GI tract. My STZ-induced diabetic mice did 
not show signs of smooth muscle dedifferentiation or altered telokin expression, 
although they did exhibit impaired colonic contactility. In these mice the colon 
motility was decreased in part due to altered calcium signaling (Figures 18, 19). 
This novel finding provides possibilities for new therapeutic targets for motility 
treatment in diabetics. 
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Figure 20. Sequence alignment of the telokin promoter. Telokin promoter 
region -190 to -94 relative to the transcription start site shows putative Sox and 
SMAD binding sites and regions used for mice T370 and T270 design. 
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